,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gdig ,,in ,,the ,,house ,,of ,,representatives ,april #aa1 #bjbb,ms4 ,slotkin introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,ways and ,means1 and ,education and ,labor1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to provide for lower prices for drugs through drug price negotiation1 and for other purposes4 #a4 ,short title2 table of contents 7a7 ,short title ,this ,act may be cited as the ,make ,medicine ,affordable ,act4 7b7 ,table of contents ,the table of contents for this ,act is as follows3 ,sec4 #a4 ,short title2 table of contents4,title ,i--,lowering ,prices ,through ,drug ,price ,negotiation,sec4 #aja4 ,providing for lower prices for certain high-priced single source drugs4,sec4 #ajb4 ,selected drug manufacturer excise tax imposed during noncompliance periods4,sec4 #ajc4 ,funding4,title ,,ii--,prescription ,drug ,inflation ,rebates,sec4 #bja4 ,medicare part ,b rebate by manufacturers4,sec4 #bjb4 ,medicare part ,d rebate by manufacturers4,title ,,iii--,part ,d ,improvements and ,maximum ,out-of-,pocket ,cap for ,medicare ,beneficiaries,sec4 #cja4 ,medicare part ,d benefit redesign4,sec4 #cjb4 ,maximum monthly cap on cost-sharing payments under prescription drug plans and ,,ma-,,pd plans4,title ,,iv--,repeal of ,certain ,prescription ,drug ,rebate ,rule,sec4 #dja4 ,prohibiting implementation of rule relating to eliminating the anti-kickback statute safe harbor protection for prescription drug rebates4,title ,v--,miscellaneous,sec4 #eja4 ,appropriate cost-sharing for certain insulin products under ,medicare part ,d4,sec4 #ejb4 ,coverage of adult vaccines recommended by the ,advisory ,committee on ,immunization ,practices under ,medicare part ,d4,sec4 #ejc4 ,payment for biosimilar biological products during initial period4,sec4 #ejd4 ,temporary increase in ,medicare part ,b payment for certain biosimilar biological products4,sec4 #eje4 ,improving access to adult vaccines under ,medicaid and ,,chip4,title ,,vi--,additional ,insulin ,policies,sec4 #fja4 ,,erisa requirements with respect to cost-sharing for certain insulin products4,sec4 #fjb4 ,public ,health ,service ,act requirements with respect to cost-sharing for insulin products4,sec4 #fjc4 ,,irc requirements with respect to cost-sharing for certain insulin products4 ,i ,lowering ,prices ,through ,drug ,price ,negotiation #aja4 ,providing for lower prices for certain high-priced single source drugs 7a7 ,program ,to lower prices for certain high-,priced single source drugs ,title ,,xi of the ,social ,security ,act is amended by adding after section #aahd 7#db ,u4,s4,c4 #acbj;e-#c7 the following new part3 ,e ,price ,negotiation ,program to ,lower ,prices for ,certain ,high-,priced ,single ,source ,drugs #aaia4 ,establishment of program 7a7 ,in general ,the ,secretary shall establish a ,drug ,price ,negotiation ,program 7in this part referred to as the program74 ,under the program1 with respect to each price applicability period1 the ,secretary shall-- 7#a7 publish a list of negotiation-eligible drugs and selected drugs in accordance with section #aaib2 7#b7 enter into agreements with manufacturers of selected drugs with respect to such period1 in accordance with section #aaic2 7#c7 negotiate and1 if applicable1 renegotiate maximum fair prices for such selected drugs1 in accordance with section #aaid2 and 7#d7 carry out the administrative duties described in section #aaif4 7b7 ,definitions relating to timing ,for purposes of this part3 7#a7 ,initial price applicability year ,the term initial price applicability year means a year 7beginning with #bjbe74 7#b7 ,price applicability period ,the term price applicability period means1 with respect to a qualifying single source drug1 the period beginning with the first initial price applicability year with respect to which such drug is a selected drug and ending with the last year during which the drug is a selected drug4 7#c7 ,selected drug publication date ,the term selected drug publication date means1 with respect to each initial price applicability year1 ,february #a of the year that begins #b years prior to such year4 7#d7 ,negotiation period ,the term negotiation period means1 with respect to an initial price applicability year with respect to a selected drug1 the period-- 7,a7 beginning on the sooner of-- 7i7 the date on which the manufacturer of the drug and the ,secretary enter into an agreement under section #aaic with respect to such drug2 or 7ii7 ,february #bh following the selected drug publication date with respect to such selected drug2 and 7,b7 ending on ,november #a of the year that begins #b years prior to the initial price applicability year4 7c7 ,other definitions ,for purposes of this part3 7#a7 ,maximum fair price eligible individual ,the term maximum fair price eligible individual means1 with respect to a selected drug-- 7,a7 in the case such drug is dispensed to the individual at a pharmacy1 by a mail order service1 or by another dispenser1 an individual who is enrolled under a prescription drug plan under part ,d of title ,,xviii or an ,,ma-,,pd plan under part ,c of such title if coverage is provided under such plan for such selected drug2 and 7,b7 in the case such drug is furnished or administered to the individual by a hospital1 physician1 or other provider of services or supplier1 an individual who is enrolled under part ,b of title ,,xviii1 including an individual who is enrolled under an ,,ma plan under part ,c of such title1 if such selected drug is covered under such part4 7#b7 ,maximum fair price ,the term maximum fair price means1 with respect to a year during a price applicability period and with respect to a selected drug 7as defined in section #aaib7;c77 with respect to such period1 the price published pursuant to section #aaie in the ,federal ,register for such drug and year4 7#c7 ,unit ,the term unit means1 with respect to a drug or biological1 the lowest identifiable amount 7such as a capsule or tablet1 milligram of molecules1 or grams7 of the drug or biological that is dispensed or furnished4 ,the determination of a unit1 with respect to a drug or biological1 pursuant to this paragraph shall not be subject to administrative or judicial review4 7#d7 ,total expenditures ,the term total expenditures includes1 in the case of expenditures with respect to part ,d of title ,,xviii1 ingredient costs1 dispensing fees1 sales tax1 and if applicable1 vaccine administration fees4 ,the term total expenditures excludes1 in the case of expenditures with respect to part ,b of such title1 expenditures for a drug or biological that are bundled or packaged into the payment for another service4 #aaib4 ,selection of negotiation-eligible drugs as selected drugs 7a7 ,in general ,not later than the selected drug publication date with respect to an initial price applicability year1 in accordance with subsection 7b71 the ,secretary shall select and publish in the ,federal ,register a list of-- 7#a7 7,a7 with respect to the initial price applicability year #bjbe1 not more than #aj negotiation-eligible drugs described in subparagraph 7,a77i7 of subsection 7d77#a71 but not subparagraph 7,b7 of such subsection1 with respect to such year2 7,b7 with respect to the initial price applicability year #bjbf1 not more than #ae negotiation-eligible drugs described in subparagraph 7,a77i7 of subsection 7d77#a71 but not subparagraph 7,b7 of such subsection1 with respect to such year2 7,c7 with respect to the initial price applicability year #bjbg1 not more than #ae negotiation-eligible drugs described in subparagraph 7,a7 of subsection 7d77#a71 but not subparagraph 7,b7 of such subsection1 with respect to such year2 and 7,d7 with respect to the initial price applicability year #bjbh or a subsequent year1 not more than #bj negotiation-eligible drugs described in subparagraph 7,a7 of subsection 7d77#a71 but not subparagraph 7,b7 of such subsection1 with respect to such year2 and 7#b7 all negotiation-eligible drugs described in subparagraph 7,b7 of such subsection with respect to such year4 ,subject to subsection 7c77#b7 and section #aaid7;f77#e71 each drug published on the list pursuant to the previous sentence shall be subject to the negotiation process under section #aaid for the negotiation period with respect to such initial price applicability year 7and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period74 7b7 ,selection of drugs 7#a7 ,in general ,in carrying out subsection 7a77#a71 subject to paragraph 7#b71 the ,secretary shall1 with respect to an initial price applicability year-- 7,a7 rank a combined list of negotiation-eligible drugs described in subsection 7d77#a77;,a7 according to the total expenditures for such drugs under parts ,b and ,d of title ,,xviii1 as determined by the ,secretary1 during the most recent period of #ab months prior to the selected drug publication date 7but ending not later than ,october #ca of the year prior to the year of such drug publication date71 with respect to such year1 for which data are available1 with the negotiation-eligible drugs with the highest total expenditures being ranked the highest2 and 7,b7 select from such ranked combined list for inclusion on the published list described in subsection 7a7 with respect to such year the negotiation-eligible drugs with the highest such rankings4 7#b7 ,high spend part ,d drugs for #bjbe and #bjbf ,with respect to the initial price applicability year #bjbe and with respect to the initial price applicability year #bjbf1 the ,secretary shall apply paragraph 7#a7 as if the reference to negotiation-eligible drugs described in subsection 7d77#a77;,a7 were a reference to negotiation-eligible drugs described in subsection 7d77#a77;,a77i7 and as if the reference to total expenditures for such drugs under parts ,b and ,d of title ,,xviii were a reference to total expenditures for such drugs under part ,d of title ,,xviii4 7c7 ,selected drug 7#a7 ,in general ,for purposes of this part1 consistent with subsection 7e77#b7 and subject to paragraph 7#b71 each negotiation-eligible drug included on the list published under subsection 7a7 with respect to an initial price applicability year shall be referred to as a selected drug with respect to such year and each subsequent year beginning before the first year that begins after the date on which the ,secretary determines at least one drug or biological product-- 7,a7 is approved or licensed 7as applicable7-- 7i7 under section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act using such drug as the listed drug2 or 7ii7 under section #cea7k7 of the ,public ,health ,service ,act using such drug as the reference product2 and 7,b7 is marketed pursuant to such approval or licensure4 7#b7 ,clarification ,a negotiation-eligible drug-- 7,a7 that is included on the list published under subsection 7a7 with respect to an initial price applicability year2 and 7,b7 for which the ,secretary makes a determination described in paragraph 7#a7 before or during the negotiation period with respect to such initial price applicability year1 shall not be subject to the negotiation process under section #aaid with respect to such negotiation period and shall continue to be considered a selected drug under this part with respect to the number of negotiation-eligible drugs published on the list under subsection 7a7 with respect to such initial price applicability year4 7d7 ,negotiation-,eligible drug 7#a7 ,in general ,for purposes of this part1 subject to paragraph 7#b71 the term negotiation-eligible drug means1 with respect to the selected drug publication date with respect to an initial price applicability year1 a qualifying single source drug1 as defined in subsection 7e71 that is described in either of the following subparagraphs 7or1 with respect to the initial price applicability year #bjbe or #bjbf1 that is described in subparagraph 7,a77i7 or 7,b773 7,a7 ,high spend drugs ,the qualifying single source drug is1 determined in accordance with subsection 7e77#b7-- 7i7 among the #ej qualifying single source drugs with the highest total expenditures under part ,d of title ,,xviii1 as determined by the ,secretary in accordance with paragraph 7#c71 during the most recent period for which data are available of at least #ab months prior to the selected drug publication date 7but ending no later than ,october #ca of the year prior to the year of such drug publication date71 with respect to such year2 or 7ii7 among the #ej qualifying single source drugs with the highest total expenditures under part ,b of title ,,xviii1 as determined by the ,secretary in accordance with paragraph 7#c71 during such most recent period1 as described in clause 7i74 7,b7 ,insulin ,the qualifying single source drug is described in subsection 7e77#a77;,c74 7#b7 ,exception for small biotech drugs 7,a7 ,in general ,subject to subparagraph 7,c71 the term negotiation-eligible drug shall not include1 with respect to the initial price applicability years #bjbe1 #bjbf1 and #bjbg1 a qualifying single source drug that meets either of the following3 7i7 ,part ,d drugs ,the total expenditures for the qualifying single source drug under part ,d of title ,,xviii1 as determined by the ,secretary in accordance with paragraph 7#c71 during #bjba-- 7,i7 are equal to or less than #a percent of the total expenditures under such part ,d1 as so determined1 for all covered part ,d drugs during such year2 and 7,,ii7 are equal to at least #hj percent of the total expenditures under such part ,d1 as so determined1 for all covered part ,d drugs for which the manufacturer of the drug has an agreement in effect under section #ahfj;,d-#ad;,a during such year4 7ii7 ,part ,b drugs ,the total expenditures for the qualifying single source drug under part ,b of title ,,xviii1 as determined by the ,secretary in accordance with paragraph 7#c71 during #bjba-- 7,i7 are equal to or less than #a percent of the total expenditures under such part ,b1 as so determined1 for all qualifying single source drugs covered under such part ,b during such year2 and 7,,ii7 are equal to at least #hj percent of the total expenditures under such part ,b1 as so determined1 for all qualifying single source drugs of the manufacturer that are covered under such part ,b during such year4 7,b7 ,clarifications relating to manufacturers 7i7 ,aggregation rule ,all persons treated as a single employer under subsection 7a7 or 7b7 of section #eb of the ,internal ,revenue ,code of #aihf shall be treated as one manufacturer for purposes of this paragraph4 7ii7 ,limitation ,a qualifying single source drug described in subparagraph 7,a7 shall not include a qualifying single source drug of a manufacturer if such manufacturer is acquired after #bjba by another manufacturer that does not meet the definition of a specified manufacturer under section #ahfj;,d-#ad;,c7g77#d77;,b77ii71 effective at the beginning of the plan year immediately following such acquisition or1 in the case of an acquisition before #bjbd1 effective ,january #a1 #bjbd4 7,c7 ,drugs not included as small biotech drugs ,the following shall not be considered a qualifying single source drug described in subparagraph 7,a73 7i7 ,a vaccine that is licensed under section #cea of the ,public ,health ,service ,act and is marketed pursuant to such section4 7ii7 ,a new formulation1 such as an extended release formulation1 of a qualifying single source drug4 7iii7 ,a qualifying single source drug described in subsection 7e77#a77;,c74 7#c7 ,clarifications and determinations 7,a7 ,previously selected drugs and small biotech drugs excluded ,in applying clauses 7i7 and 7ii7 of paragraph 7#a77;,a71 the ,secretary shall not consider or count-- 7i7 drugs that are already selected drugs2 and 7ii7 for initial price applicability years #bjbe1 #bjbf1 and #bjbg1 qualifying single source drugs described in paragraph 7#b77;,a74 7,b7 ,use of data ,in determining whether a qualifying single source drug satisfies any of the criteria described in paragraph 7#a7 or 7#b71 the ,secretary shall use data that is aggregated across dosage forms and strengths of the drug1 including new formulations of the drug1 such as an extended release formulation1 and not based on the specific formulation or package size or package type of the drug4 7#d7 ,publication ,not later than the selected drug publication date with respect to an initial price applicability year1 the ,secretary shall publish in the ,federal ,register a list of negotiation-eligible drugs with respect to such selected drug publication date4 7e7 ,qualifying single source drug 7#a7 ,in general ,for purposes of this part1 the term qualifying single source drug means1 with respect to an initial price applicability year1 subject to paragraphs 7#b7 and 7#c71 a covered part ,d drug 7as defined in section #ahfj;,d-#b7;e77 that is described in any of the following or a drug or biological product covered under part ,b of title ,,xviii that is described in any of the following3 7,a7 ,drug products ,a drug-- 7i7 that is approved under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act and is marketed pursuant to such approval2 7ii7 for which1 as of the selected drug publication date with respect to such initial price applicability year1 at least #g years will have elapsed since the date of such approval2 and 7iii7 that is not the listed drug for any drug that is approved and marketed under section #eje7;j7 of such ,act4 7,b7 ,biological products ,a biological product-- 7i7 that is licensed under section #cea7;a7 of the ,public ,health ,service ,act and is marketed under section #cea of such ,act2 7ii7 for which1 as of the selected drug publication date with respect to such initial price applicability year1 at least #aa years will have elapsed since the date of such licensure2 and 7iii7 that is not the reference product for any biological product that is licensed and marketed under section #cea7k7 of such ,act4 7,c7 ,insulin product ,any insulin product that is approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act or licensed under section #cea of the ,public ,health ,service ,act and marketed pursuant to such approval or licensure1 including any insulin product that has been deemed to be licensed under section #cea of the ,public ,health ,service ,act pursuant to section #gjjb7;e77#d7 of the ,biologics ,price ,competition and ,innovation ,act of #bjji and is marketed pursuant to such section1 regardless of whether such insulin product would be described in subparagraph 7,a7 or 7,b74 7#b7 ,treatment of authorized generic drugs 7,a7 ,in general ,in the case of a qualifying single source drug described in subparagraph 7,a7 or 7,b7 of paragraph 7#a7 that is the listed drug 7as such term is used in section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act7 or the reference product 7as defined in section #cea7;i7 of the ,public ,health ,service ,act71 with respect to an authorized generic drug1 in applying the provisions of this part1 such authorized generic drug and such listed drug or reference product shall be treated as the same qualifying single source drug4 7,b7 ,authorized generic drug defined ,for purposes of this paragraph1 the term authorized generic drug means-- 7i7 in the case of a drug1 an authorized generic drug 7as such term is defined in section #eje7t77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act72 and 7ii7 in the case of a biological product1 a reference product 7as such term is defined in section #cea7;i7 of the ,public ,health ,service ,act7 that-- 7,i7 has been licensed under section #cea7;a7 of such ,act2 and 7,,ii7 is marketed1 sold1 or distributed directly or indirectly to retail class of trade under a different labeling1 packaging 7other than repackaging as the reference product in blister packs1 unit doses1 or similar packaging for use in institutions71 product code1 labeler code1 trade name1 or trade mark than the reference product4 7#c7 ,exclusions ,in this part1 the term qualifying single source drug does not include any of the following3 7,a7 ,certain orphan drugs ,a drug that is designated as a drug for only one rare disease or condition under section #ebf of the ,federal ,food1 ,drug1 and ,cosmetic ,act and for which the only approved indication 7or indications7 is for such disease or condition4 7,b7 ,low spend ,medicare drugs ,a drug or biological product 7other than an insulin product described in paragraph 7#a77;,c77 with respect to which the total expenditures under parts ,b and ,d of title ,,xviii1 as determined by the ,secretary1 during the most recent period for which data are available of at least #ab months prior to the selected drug publication date 7but ending no later than ,october #ca of the year prior to the year of such drug publication date71 with respect to such year is less than-- 7i7 with respect to #bjba1 #bjj1jjj1jjj2 or 7ii7 with respect to a subsequent year1 the dollar amount specified in this subparagraph for the previous year increased by the annual percentage increase in the consumer price index 7all items2 ,u4,s4 city average7 as of ,december of such previous year4 7f7 ,no administrative or judicial review of determinations and selections ,the determination of negotiation-eligible drugs under subsection 7d7 and the selection of drugs under this section are not subject to administrative or judicial review4 #aaic4 ,manufacturer agreements 7a7 ,in general ,for purposes of section #aaia7;a77#b71 the ,secretary shall enter into agreements with manufacturers of selected drugs with respect to a price applicability period1 by not later than ,february #bh following the selected drug publication date with respect to such selected drug1 under which-- 7#a7 during the negotiation period for the initial price applicability year for the selected drug1 the ,secretary and manufacturer1 in accordance with section #aaid1 negotiate to determine 7and1 by not later than the last date of such period1 agree to7 a maximum fair price for such selected drug of the manufacturer in order for the manufacturer to provide access to such price-- 7,a7 to maximum fair price eligible individuals who with respect to such drug are described in subparagraph 7,a7 of section #aaia7;c77#a7 and are dispensed such drug 7and to pharmacies1 mail order services1 and other dispensers1 with respect to such maximum fair price eligible individuals who are dispensed such drugs7 during1 subject to subparagraph 7#b71 the price applicability period2 and 7,b7 to hospitals1 physicians1 and other providers of services and suppliers with respect to maximum fair price eligible individuals who with respect to such drug are described in subparagraph 7,b7 of such section and are furnished or administered such drug during1 subject to subparagraph 7#b71 the price applicability period2 7#b7 the ,secretary and the manufacturer shall1 in accordance with section #aaid1 renegotiate 7and1 by not later than the last date of such period1 agree to7 the maximum fair price for such drug1 in order for the manufacturer to provide access to such maximum fair price 7as so renegotiated7-- 7,a7 to maximum fair price eligible individuals who with respect to such drug are described in subparagraph 7,a7 of section #aaia7;c77#a7 and are dispensed such drug 7and to pharmacies1 mail order services1 and other dispensers1 with respect to such maximum fair price eligible individuals who are dispensed such drugs7 during any year during the price applicability period 7beginning after such renegotiation7 with respect to such selected drug2 and 7,b7 to hospitals1 physicians1 and other providers of services and suppliers with respect to maximum fair price eligible individuals who with respect to such drug are described in subparagraph 7,b7 of such section and are furnished or administered such drug during any year described in subparagraph 7,a72 7#c7 access to the maximum fair price 7including as renegotiated pursuant to paragraph 7#b771 with respect to such a selected drug1 shall be provided by the manufacturer to-- 7,a7 maximum fair price eligible individuals1 who with respect to such drug are described in subparagraph 7,a7 of section #aaia7;c77#a71 at the pharmacy1 mail order service1 or other dispenser at the point-of-sale of such drug 7and shall be provided by the manufacturer to the pharmacy1 mail order service1 or other dispenser1 with respect to such maximum fair price eligible individuals who are dispensed such drugs71 as described in paragraph 7#a77;,a7 or 7#b77;,a71 as applicable2 and 7,b7 hospitals1 physicians1 and other providers of services and suppliers with respect to maximum fair price eligible individuals who with respect to such drug are described in subparagraph 7,b7 of such section and are furnished or administered such drug1 as described in paragraph 7#a77;,b7 or 7#b77;,b71 as applicable2 7#d7 the manufacturer1 subject to subsection 7d71 submits to the ,secretary1 through an online portal established by the ,secretary or other form and manner specified by the ,secretary1 for the negotiation period for the price applicability period 7and1 if applicable1 before any period of renegotiation pursuant to section #aaid7;f77 with respect to such drug-- 7,a7 information on the non-,federal average manufacturer price for the drug for the applicable year or period2 and 7,b7 all other information that the ,secretary requires to carry out the negotiation 7or renegotiation process7 under this part1 including information described in section #aaid7;e77#a72 and 7#e7 the manufacturer complies with requirements imposed by the ,secretary for purposes of administering the program1 including with respect to the duties described in section #aaif4 7b7 ,agreement in effect until drug is no longer a selected drug ,an agreement entered into under this section shall be effective1 with respect to a selected drug1 until such drug is no longer considered a selected drug under section #aaib7;c74 7c7 ,confidentiality of information ,information submitted to the ,secretary under this part by a manufacturer of a selected drug that is proprietary information of such manufacturer 7as determined by the ,secretary7 shall be used only by the ,secretary or disclosed to and used by the ,comptroller ,general of the ,united ,states or the ,medicare ,payment ,advisory ,commission for purposes of carrying out this part4 7d7 ,implementation for #bjbe and #bjbf ,notwithstanding any other provision of this part1 the ,secretary shall implement this section for #bjbe and #bjbf by program instruction or otherwise4 #aaid4 ,negotiation and renegotiation process 7a7 ,in general ,for purposes of this part1 under an agreement under section #aaic between the ,secretary and a manufacturer of a selected drug1 with respect to the period for which such agreement is in effect and in accordance with subsections 7b71 7c71 and 7d71 the ,secretary and the manufacturer-- 7#a7 shall during the negotiation period with respect to such drug1 in accordance with this section1 negotiate a maximum fair price for such drug for the purpose described in section #aaic7;a77#a72 and 7#b7 renegotiate1 in accordance with the process specified pursuant to subsection 7f71 such maximum fair price for such drug if such drug is a renegotiation-eligible drug under such subsection4 7b7 ,negotiation process requirements 7#a7 ,methodology and process ,the ,secretary shall develop and use a consistent methodology and process1 in accordance with paragraph 7#b71 for negotiations under subsection 7a7 that aims to achieve the lowest maximum fair price for each selected drug4 7#b7 ,specific elements of negotiation process ,as part of the negotiation process under this section1 with respect to a selected drug and the negotiation period with respect to the initial price applicability year with respect to such drug1 the following shall apply3 7,a7 ,submission of information ,not later than ,march #a of the year of the selected drug publication date1 with respect to the selected drug1 the manufacturer of the drug shall submit to the ,secretary1 in accordance with section #aaic7;a77#d71 the information described in such section4 7,b7 ,initial offer by ,secretary ,not later than the ,june #a following the selected drug publication date1 the ,secretary shall provide the manufacturer of a selected drug with a written initial offer that contains the ,secretary's proposal for the maximum fair price of the drug and a list of the considerations described in section #aaid7;e7 that were used in developing such offer4 7,c7 ,response to initial offer 7i7 ,in general ,not later than #cj days after the date of receipt of an initial offer under subparagraph 7,b71 the manufacturer shall either accept such offer or propose a counteroffer to such offer4 7ii7 ,counteroffer requirements ,if a manufacturer proposes a counteroffer1 such counteroffer-- 7,i7 shall be in writing2 and 7,,ii7 shall be justified based on the factors described in subsection 7e74 7,d7 ,response to counteroffer ,after receiving a counteroffer under subparagraph 7,c71 the ,secretary shall respond in writing to such counteroffer4 7,e7 ,deadline ,all negotiations shall end prior to the first day of ,november following the selected drug publication date1 with respect to the initial price applicability year4 7,f7 ,limitations on offer amount ,in negotiating the maximum fair price of a selected drug1 with respect to an initial price applicability year for the selected drug1 and1 as applicable1 in renegotiating the maximum fair price for such drug1 with respect to a subsequent year during the price applicability period for such drug1 the ,secretary shall not offer 7or agree to a counteroffer for7 a maximum fair price for the selected drug that-- 7i7 exceeds the ceiling determined under subsection 7c7 for the selected drug and year2 or 7ii7 as applicable1 is less than the floor determined under subsection 7d7 for the selected drug and year4 7,g7 ,treatment of determination ,the establishment of a maximum fair price under this section is not subject to administrative or judicial review4 7c7 ,ceiling for maximum fair price 7#a7 ,in general ,the maximum fair price negotiated under this section for a selected drug1 with respect to the first year of the price applicability period with respect to such drug1 shall not exceed the applicable percent described in paragraph 7#b71 with respect to such drug1 of the following3 7,a7 ,initial price applicability year #bjbe ,in the case of a selected drug with respect to which such initial price applicability year is #bjbe1 the average of the non-,federal average manufacturer price for such drug for the first #c calendar quarters of #bjba 7or1 in the case that there is not a non-,federal average manufacturer price available for such drug for any of such first #c calendar quarters of #bjba1 for the first full year following the market entry for such drug71 increased by the percentage increase in the consumer price index for all urban consumers 7all items2 ,united ,states city average7 from ,september #bjba 7or such first full year following the market entry71 as applicable1 to the year prior to the selected drug publication date with respect to such initial price applicability year4 7,b7 ,initial price applicability year #bjbf and subsequent years ,in the case of a selected drug with respect to which such initial price applicability year is #bjbf or a subsequent year1 the lower of-- 7i7 the average of the non-,federal average manufacturer price for such drug for the first #c calendar quarters of #bjba 7or1 in the case that there is not a non-,federal average manufacturer price available for such drug for any of such first #c calendar quarters of #bjba1 for the first full year following the market entry for such drug71 increased by the percentage increase in the consumer price index for all urban consumers 7all items2 ,united ,states city average7 from ,september #bjba 7or such first full year following the market entry71 as applicable1 to the year prior to the selected drug publication date with respect to such initial price applicability year2 or 7ii7 the non-,federal average manufacturer price for such drug for the year prior to the selected drug publication date with respect to such initial price applicability year4 7#b7 ,applicable percent described ,for purposes of paragraph 7#a71 the applicable percent described in this paragraph is the following3 7,a7 ,short-monopoly drugs ,with respect to a selected drug 7other than a post-exclusivity drug and a long-monopoly drug71 #ge percent4 7,b7 ,post-exclusivity drugs ,with respect to a post-exclusivity drug1 #fe percent4 7,c7 ,long-monopoly drugs ,with respect to a long-monopoly drug1 #dj percent4 7#c7 ,post-exclusivity drug defined 7,a7 ,in general ,in this part1 subject to subparagraph 7,b71 the term post-exclusivity drug means1 with respect to an initial price applicability year1 a selected drug for which at least #ab years1 but fewer than #af years1 have elapsed since the date of approval of such drug under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or since the date of licensure of such drug under section #cea7;a7 of the ,public ,health ,service ,act1 as applicable4 7,b7 ,exclusions ,the term post-exclusivity drug shall not include any of the following3 7i7 ,a vaccine that is licensed under section #cea of the ,public ,health ,service ,act and marketed pursuant to such section4 7ii7 ,a selected drug that had an agreement under this part with the ,secretary prior to the initial price applicability year #bjcj4 7,c7 ,clarification ,nothing in subparagraph 7,b77ii7 shall limit the transition of a selected drug described in paragraph 7#b77;,a7 to a long-monopoly drug if the selected drug meets the definition of a long-monopoly drug4 7#d7 ,long-monopoly drug defined 7,a7 ,in general ,in this part1 subject to subparagraph 7,b71 the term long-monopoly drug means1 with respect to an initial price applicability year1 a selected drug for which at least #af years have elapsed since the date of approval of such drug under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or since the date of licensure of such drug under section #cea7;a7 of the ,public ,health ,service ,act1 as applicable4 7,b7 ,exclusion ,the term long-monopoly drug shall not include a vaccine that is licensed under section #cea of the ,public ,health ,service ,act and marketed pursuant to such section4 7#e7 ,non-,federal average manufacturer price ,in this part1 the term non-,federal average manufacturer price has the meaning given such term in section #habf7;h77#e7 of title #ch1 ,united ,states ,code4 7d7 ,temporary floor for small biotech drugs ,in the case of a selected drug that is a qualifying single source drug described in section #aaib7;d77#b7 and with respect to which the first initial price applicability year of the price applicability period with respect to such drug is #bjbh or #bjbi1 the maximum fair price negotiated under this section for such drug for such initial price applicability year may not be less than #ff percent of the average of the non-,federal average manufacturer price for such drug 7as defined and applied in subsection 7c77#d77 for the first #c calendar quarters of #bjba 7or1 in the case that there is not a non-,federal average manufacturer price available for such drug for any of such first #c calendar quarters of #bjba1 for the first full year following the market entry for such drug71 increased by the percentage increase in the consumer price index for all urban consumers 7all items2 ,united ,states city average7 from ,september #bjba 7or such first full year following the market entry71 as applicable1 to the year prior to the selected drug publication date with respect to the initial price applicability year4 7e7 ,considerations ,for purposes of negotiating the maximum fair price of a selected drug under this part with the manufacturer of the drug1 the ,secretary shall consider the following factors 7and1 with respect to post-exclusivity drugs and long-monopoly drugs1 shall not consider factors other than those described in subparagraphs 7,b7 and 7,c7 of paragraph 7#a773 7#a7 ,manufacturer-specific information ,the following information1 with respect to such selected drug1 including as submitted by the manufacturer3 7,a7 ,research and development costs of the manufacturer for the drug and the extent to which the manufacturer has recouped research and development costs4 7,b7 ,market data for the drug1 including the distribution of sales across different programs and purchasers and projected future revenues for the drug4 7,c7 ,unit costs of production and distribution of the drug4 7,d7 ,prior ,federal financial support for novel therapeutic discovery and development with respect to the drug4 7,e7 ,data on patents and on existing and pending exclusivity for the drug4 7,f7 ,national sales data for the drug4 7,g7 ,information on clinical trials for the drug4 7#b7 ,information on unmet medical needs and alternative treatments ,the following information1 with respect to such selected drug3 7,a7 ,the extent to which the drug represents a therapeutic advance as compared to existing therapeutic alternatives and1 to the extent such information is available1 the costs of such existing therapeutic alternatives4 7,b7 ,information on approval by the ,food and ,drug ,administration of alternative drug products or biological products4 7,c7 ,information on comparative effectiveness analysis for such products1 taking into consideration the effects of such products on specific populations1 such as individuals with disabilities1 the elderly1 the terminally ill1 children1 and other patient populations4 7,d7 ,the extent to which the drug addresses unmet medical needs for a condition for which treatment or diagnosis is not addressed adequately by available therapy4 ,in considering information described in subparagraph 7,c71 the ,secretary shall not use evidence or findings from comparative clinical effectiveness research in a manner that treats extending the life of an elderly1 disabled1 or terminally ill individual as of lower value than extending the life of an individual who is younger1 nondisabled1 or not terminally ill4 7#c7 ,additional information ,information submitted to the ,secretary1 in accordance with a process specified by the ,secretary1 by other parties that are affected by the establishment of a maximum fair price for the selected drug4 7f7 ,renegotiation process 7#a7 ,in general ,in the case of a renegotiation-eligible drug 7as defined in paragraph 7#b77 that is selected under paragraph 7#c71 the ,secretary shall provide for a process of renegotiation 7for years 7beginning with #bjbg7 during the price applicability period1 with respect to such drug7 of the maximum fair price for such drug consistent with paragraph 7#d74 7#b7 ,renegotiation-eligible drug defined ,in this section1 the term renegotiation-eligible drug means a selected drug that is any of the following3 7,a7 ,addition of new indication ,a selected drug for which a new indication is added to the drug4 7,b7 ,change of status to a post-exclusivity drug ,a selected drug that is described in section #aaib7;d77#a77;,a7 that-- 7i7 is not a post-exclusivity drug or a long-monopoly drug2 and 7ii7 for which there is a change in status to that of a post-exclusivity drug4 7,c7 ,change of status to a long-monopoly drug ,a selected drug that is described in section #aaib7;d77#a77;,a7 that-- 7i7 is not a long-monopoly drug2 and 7ii7 for which there is a change in status to that of a long-monopoly drug4 7,d7 ,material changes ,a selected drug for which the ,secretary determines there has been a material change of factors described in paragraph 7#a7 or 7#b7 of subsection 7e74 7#c7 ,selection of drugs for renegotiation ,each year the ,secretary shall select among renegotiation-eligible drugs for renegotiation as follows3 7,a7 ,all post-exclusivity negotiation-eligible drugs ,the ,secretary shall select all renegotiation-eligible drugs described in paragraph 7#b77;,b74 7,b7 ,all long-monopoly negotiation-eligible drugs ,the ,secretary shall select all renegotiation-eligible drugs described in paragraph 7#b77;,c74 7,c7 ,remaining drugs ,among the remaining renegotiation-eligible drugs described in subparagraphs 7,a7 and 7,d7 of paragraph 7#b71 the ,secretary shall select renegotiation-eligible drugs for which the ,secretary expects renegotiation is likely to result in a significant change in the maximum fair price otherwise negotiated4 7#d7 ,renegotiation process ,the ,secretary shall specify the process for renegotiation of maximum fair prices with the manufacturer of a renegotiation-eligible drug selected for renegotiation under this subsection4 ,such process shall1 to the extent practicable1 be consistent with the methodology and process established under subsection 7b7 and in accordance with subsections 7c7 and 7d71 and for purposes of applying subsections 7c7 and 7d71 the reference to the first initial price applicability year of the price applicability period with respect to such drug shall be treated as the first initial price applicability year of such period for which the maximum fair price established pursuant to such renegotiation applies1 including for applying subsection 7c77#b77;,b7 in the case of renegotiation-eligible drugs described in paragraph 7#c77;,a7 of this subsection and subsection 7c77#b77;,c7 in the case of renegotiation-eligible drugs described in paragraph 7#c77;,b7 of this subsection4 7#e7 ,clarification ,a renegotiation-eligible drug for which the ,secretary makes a determination described in section #aaib7;c77#a7 before or during the period of renegotiation shall not be subject to the renegotiation process under this section4 7#f7 ,no administrative or judicial review ,the determination of renegotiation-eligible drugs under paragraph 7#b7 and the selection of renegotiation-eligible drugs under paragraph 7#c7 are not subject to administrative or judicial review4 7g7 ,request for information ,for purposes of negotiating and1 as applicable1 renegotiating 7including for purposes of determining whether to renegotiate7 the maximum fair price of a selected drug under this part with the manufacturer of the drug1 with respect to a price applicability period1 and other relevant data for purposes of this section-- 7#a7 the ,secretary shall1 not later than the selected drug publication date with respect to the initial price applicability year of such period1 request drug pricing information from the manufacturer of such selected drug1 including information described in subsection 7e77#a72 and 7#b7 by not later than ,march #a following the selected drug publication date1 the manufacturer of such selected drug shall submit to the ,secretary such requested information in such form and manner as the ,secretary requires4 ,the ,secretary shall request1 from the manufacturer or others1 all additional information needed to carry out the negotiation and renegotiation process under this section4 7h7 ,clarification ,in no case shall the maximum fair price negotiated under this section for a selected drug that is a qualifying single source drug described in subparagraph 7,a7 or 7,b7 of section #aaib7;e77#a7 apply before-- 7#a7 in the case the selected drug is a qualifying single source drug described in such subparagraph 7,a71 the date that is #i years after the date on which the drug was approved under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act2 and 7#b7 in the case the selected drug is a qualifying single source drug described in such subparagraph 7,b71 the date that is #ac years after the date on which the drug was licensed under section #cea7;a7 of the ,public ,health ,service ,act4 7i7 ,implementation for #bjbe and #bjbf ,notwithstanding any other provision of this part1 the ,secretary shall implement this section for #bjbe and #bjbf by program instruction or otherwise4 #aaie4 ,publication of maximum fair prices 7a7 ,in general ,with respect to an initial price applicability year and a selected drug with respect to such year-- 7#a7 not later than ,november #ae of the year that is #b years prior to such initial price applicability year1 the ,secretary shall publish on ,,cms4gov the maximum fair price for such drug negotiated under this part with the manufacturer of such drug2 7#b7 not later than ,november #cj of the year that is #b years prior to such initial price applicability year1 the ,secretary shall publish in the ,federal ,register the maximum fair price for such drug described in paragraph 7#a72 and 7#c7 not later than ,march #a of the year prior to such initial price applicability year1 the ,secretary shall publish in the ,federal ,register1 subject to section #aaic7;c7 and based on the considerations as described in section #aaid7;e71 the explanation for the maximum fair price for such drug described in paragraphs 7#a7 and 7#b74 7b7 ,updates 7#a7 ,subsequent year maximum fair prices ,for a selected drug1 for each year subsequent to first initial price applicability year of the price applicability period with respect to such drug1 with respect to which an agreement for such drug is in effect under section #aaic1 not later than ,november #cj of the year that is #b years prior to such subsequent year1 the ,secretary shall publish in the ,federal ,register the maximum fair price applicable to such drug and year1 which shall be-- 7,a7 subject to subparagraph 7,b71 the amount equal to the maximum fair price published for such drug for the previous year1 increased by the annual percentage increase in the consumer price index for all urban consumers 7all items2 ,u4,s4 city average7 as of ,september of such previous year2 or 7,b7 in the case the maximum fair price for such drug was renegotiated1 for the first year for which such price as so renegotiated applies1 such renegotiated maximum fair price4 7#b7 ,prices negotiated after deadline ,in the case of a selected drug with respect to an initial price applicability year for which the maximum fair price is determined under this part after the date of publication under this section1 the ,secretary shall publish such maximum fair price in the ,federal ,register by not later than #cj days after the date such maximum price is so determined4 #aaif4 ,administrative duties2 coordination provisions 7a7 ,administrative duties 7#a7 ,in general ,for purposes of section #aaia1 the administrative duties described in this section are the following3 7,a7 ,the establishment of procedures to ensure that the maximum fair price for a selected drug is applied before-- 7i7 any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of maximum fair price eligible individuals2 and 7ii7 any other discounts4 7,b7 ,the establishment of procedures to compute and apply the maximum fair price across different strengths and dosage forms of a selected drug and not based on the specific formulation or package size or package type of the drug4 7,c7 ,the establishment of procedures to carry out the provisions of this part1 as applicable1 with respect to-- 7i7 maximum fair price eligible individuals who are enrolled under a prescription drug plan under part ,d of title ,,xviii or an ,,ma-,,pd plan under part ,c of such title2 and 7ii7 maximum fair price eligible individuals who are enrolled under part ,b of such title1 including who are enrolled under an ,,ma plan under part ,c of such title4 7,d7 ,the establishment of a negotiation process and renegotiation process in accordance with section #aaid1 including a process for acquiring information described in subsection 7e7 of such section4 7,e7 ,the establishment of an online portal which manufacturers shall be required to use to submit information described in section #aaid7;b77#b77;,a74 7,f7 ,the sharing with the ,secretary of the ,treasury of such information as is necessary to determine the tax imposed by section #daib of the ,internal ,revenue ,code of #aihf 7relating to enforcement of this part74 7,g7 ,the establishment of an attestation and verification process for purposes of applying section #aaib7;d77#b77;,b74 7#b7 ,monitoring compliance ,the ,secretary shall monitor compliance by a manufacturer with the terms of an agreement under section #aaic1 including by establishing a mechanism through which violations of such terms shall be reported4 7b7 ,implementation for #bjbe and #bjbf ,notwithstanding any other provision of this part1 the ,secretary shall implement this section for #bjbe and #bjbf by program instruction or otherwise4 #aaig4 ,civil monetary penalty 7a7 ,violations relating to offering of maximum fair price ,any manufacturer of a selected drug that has entered into an agreement under section #aaic1 with respect to a year during the price applicability period with respect to such drug1 that does not provide access to a price that is not more than the maximum fair price 7or a lesser price7 for such drug for such year-- 7#a7 to a maximum fair price eligible individual who with respect to such drug is described in subparagraph 7,a7 of section #aaia7;c77#a7 and who is dispensed such drug during such year 7and to pharmacies1 mail order services1 and other dispensers1 with respect to such maximum fair price eligible individuals who are dispensed such drugs72 or 7#b7 to a hospital1 physician1 or other provider of services or supplier with respect to maximum fair price eligible individuals who with respect to such drug is described in subparagraph 7,b7 of such section and is furnished or administered such drug by such hospital1 physician1 or provider or supplier during such year1 shall be subject to a civil monetary penalty equal to ten times the amount equal to the product of the number of units of such drug so furnished1 dispensed1 or administered during such year and the difference between the price for such drug made available for such year by such manufacturer with respect to such individual or hospital1 physician1 provider of services1 or supplier and the maximum fair price for such drug for such year4 7b7 ,violations of certain terms of agreement ,any manufacturer of a selected drug that has entered into an agreement under section #aaic1 with respect to a year during the price applicability period with respect to such drug1 that is in violation of a requirement imposed pursuant to section #aaic7;a77#e71 including the requirement to submit information pursuant to section #aaic7;a77#d71 shall be subject to a civil monetary penalty equal to #a1jjj1jjj for each day of such violation4 7c7 ,false information ,any manufacturer that knowingly provides false information for the attestation process or verification process established pursuant to section #aaif7;a77#a77;,h71 shall be subject to a civil monetary penalty equal to #ajj1jjj1jjj for each item of such false information4 7d7 ,application ,the provisions of section #aabh;,a 7other than subsections 7a7 and 7b77 shall apply to a civil monetary penalty under this section in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a7a74 4 7b7 ,application of maximum fair prices and conforming amendments 7#a7 ,under ,medicare 7,a7 ,application to payments under part ,b ,section #ahdg;,a7b77#a77;,b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7b77#a77;,b77 is amended by inserting or in the case of such a drug or biological that is a selected drug 7as referred to in section #aaib7;c771 with respect to a price applicability period 7as defined in section #aaia7;b77#b771 #ajf percent of the maximum fair price 7as defined in section #aaia7;c77#b77 applicable for such drug and a year during such period after paragraph 7#d74 7,b7 ,application under ,,ma of cost-sharing for part ,b drugs based off of negotiated price ,section #aheb7;a77#a77;,b77iv7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bb7;a77#a77;,b77iv77 is amended-- 7i7 by redesignating subclause 7,,vii7 as subclause 7,,viii72 and 7ii7 by inserting after subclause 7,,vi7 the following subclause3 7,,vii7 ,a drug or biological that is a selected drug 7as referred to in section #aaib7;c774 4 7,c7 ,exception to part ,d non-interference ,section #ahfj;,d-#aa7;i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;i77 is amended-- 7i7 in paragraph 7#a71 by striking and at the end2 7ii7 in paragraph 7#b71 by striking or institute a price structure for the reimbursement of covered part ,d drugs and inserting for covered part ,d drugs2 and2 and 7iii7 by adding at the end the following3 7#c7 may not institute a price structure for the reimbursement of covered part ,d drugs1 except as provided under part ,e of title ,,xi4 4 7,d7 ,application as negotiated price under part ,d ,section #ahfj;,d-#b7;d77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;d77#a77 is amended-- 7i7 in subparagraph 7,b71 by inserting 1 subject to subparagraph 7,d71 after negotiated prices2 and 7ii7 by adding at the end the following new subparagraph3 7,d7 ,application of maximum fair price for selected drugs ,in applying this section1 in the case of a covered part ,d drug that is a selected drug 7as referred to in section #aaib7;c771 with respect to a price applicability period 7as defined in section #aaia7;b77#b771 the negotiated prices used for payment 7as described in this subsection7 shall be no greater than the maximum fair price 7as defined in section #aaia7;c77#b77 for such drug and for each year during such period plus any dispensing fees for such drug4 4 7,e7 ,coverage of selected drugs ,section #ahfj;,d-#d7;b77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7;b77#c77 is amended by adding at the end the following new subparagraph3 7,i7 ,required inclusion of selected drugs ,for #bjbe and each subsequent year1 the ,,pdp sponsor offering a prescription drug plan shall include each covered part ,d drug that is a selected drug under section #aaib for which an agreement for such drug is in effect under section #aaic with respect to the year4 4 7,f7 ,information from prescription drug plans and ,,ma-,,pd plans required 7i7 ,prescription drug plans ,section #ahfj;,d-#ab7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aab7;b77 is amended by adding at the end the following new paragraph3 7#h7 ,provision of information related to maximum fair prices ,each contract entered into with a ,,pdp sponsor under this part with respect to a prescription drug plan offered by such sponsor shall require the sponsor to provide information to the ,secretary as requested by the ,secretary in accordance with section #aaid7;g74 4 7ii7 ,,ma-,,pd plans ,section #aheg7;f77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bg7;f77#c77 is amended by adding at the end the following new subparagraph3 7,e7 ,provision of information related to maximum fair prices ,section #ahfj;,d-#ab7;b77#h74 4 7#b7 ,drug price negotiation program prices included in best price ,section #aibg7;c77#a77;,c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;c77#a77;,c77 is amended-- 7,a7 in clause 7i77,,vi71 by striking any prices charged and inserting subject to clause 7ii77,v71 any prices charged2 and 7,b7 in clause 7ii7-- 7i7 in subclause 7,,iii71 by striking at the end 2 and2 7ii7 in subclause 7,,iv71 by striking at the end the period and inserting 2 and2 and 7iii7 by adding at the end the following new subclause3 7,v7 in the case of a rebate period and a covered outpatient drug that is a selected drug 7as referred to in section #aaib7;c77 during such rebate period1 shall be inclusive of the maximum fair price 7as defined in section #aaia7;c77#b77 for such drug with respect to such period4 4 #ajb4 ,selected drug manufacturer excise tax imposed during noncompliance periods 7a7 ,in general ,chapter #cb of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new subchapter3 ,e ,other items ,sec4 #daib4 ,selected drugs during noncompliance periods4 #daib4 ,selected drugs during noncompliance periods 7a7 ,in general ,there is hereby imposed on the sale by the manufacturer1 producer1 or importer of any selected drug during a day described in subsection 7b7 a tax in an amount such that the applicable percentage is equal to the ratio of-- 7#a7 such tax1 divided by 7#b7 the sum of such tax and the price for which so sold4 7b7 ,noncompliance periods ,a day is described in this subsection with respect to a selected drug if it is a day during one of the following periods3 7#a7 ,the period beginning on the ,march #ast immediately following the selected drug publication date and ending on the first date during which the manufacturer of the drug has in place an agreement described in subsection 7a7 of section #aaic of the ,social ,security ,act with respect to such drug4 7#b7 ,the period beginning on the ,november #bnd immediately following the ,march #ast described in paragraph 7#a7 and ending on the first date during which the manufacturer of the drug and the ,secretary have agreed to a maximum fair price under such agreement4 7#c7 ,in the case of a selected drug with respect to which the ,secretary of ,health and ,human ,services has specified a renegotiation period under such agreement1 the period beginning on the first date after the last date of such renegotiation period and ending on the first date during which the manufacturer of the drug has agreed to a renegotiated maximum fair price under such agreement4 7#d7 ,with respect to information that is required to be submitted to the ,secretary of ,health and ,human ,services under such agreement1 the period beginning on the date on which such ,secretary certifies that such information is overdue and ending on the date that such information is so submitted4 7c7 ,applicable percentage ,for purposes of this section1 the term applicable percentage means-- 7#a7 in the case of sales of a selected drug during the first #ij days described in subsection 7b7 with respect to such drug1 #fe percent1 7#b7 in the case of sales of such drug during the #iast day through the #ahjth day described in subsection 7b7 with respect to such drug1 #ge percent1 7#c7 in the case of sales of such drug during the #ahast day through the #bgjth day described in subsection 7b7 with respect to such drug1 #he percent1 and 7#d7 in the case of sales of such drug during any subsequent day1 #ie percent4 7d7 ,selected drug ,for purposes of this section-- 7#a7 ,in general ,the term selected drug means any selected drug 7within the meaning of section #aaib of the ,social ,security ,act7 which is manufactured or produced in the ,united ,states or entered into the ,united ,states for consumption1 use1 or warehousing4 7#b7 ,united ,states ,the term ,united ,states has the meaning given such term by section #dfab7;a77#d74 7#c7 ,coordination with rules for possessions of the ,united ,states ,rules similar to the rules of paragraphs 7#b7 and 7#d7 of section #dacb7;c7 shall apply for purposes of this section4 7e7 ,other definitions ,for purposes of this section1 the terms selected drug publication date and maximum fair price have the meaning given such terms in section #aaia of the ,social ,security ,act4 7f7 ,anti-,abuse rule ,in the case of a sale which was timed for the purpose of avoiding the tax imposed by this section1 the ,secretary may treat such sale as occurring during a day described in subsection 7b74 4 7b7 ,no deduction for excise tax payments ,section #bge7;a77#f7 of the ,internal ,revenue ,code of #aihf is amended by inserting or by section #daib before the period at the end4 7c7 ,certain exemptions from tax not applicable 7#a7 ,section #dbba7;a7 of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following3 ,in the case of the tax imposed by section #daib1 paragraphs 7#c71 7#d71 7#e71 and 7#f7 shall not apply44 7#b7 ,section #fdaf7;b77#b7 of such ,code is amended by adding at the end the following3 ,in the case of the tax imposed by section #daib1 subparagraphs 7,b71 7,c71 7,d71 and 7,e7 shall not apply44 7d7 ,clerical amendment ,the table of subchapters for chapter #cb of such ,code is amended by adding at the end the following new item3 ,subchapter ,e4 ,other items 4 7e7 ,effective date ,the amendments made by this section shall apply to sales after the date of the enactment of this ,act4 #ajc4 ,funding ,in addition to amounts otherwise available1 there is appropriated for fiscal year #bjbb1 out of any money in the ,treasury not otherwise appropriated1 to remain available until expended-- 7#a7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbb2 7#b7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbc2 7#c7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbd2 7#d7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbe2 7#e7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbf2 7#f7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbg2 7#g7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbh2 7#h7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjbi2 7#i7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjcj2 and 7#aj7 #cjj1jjj1jjj to carry out the provisions of1 including the amendments made by1 this part in fiscal year #bjca4 ,,ii ,prescription ,drug ,inflation ,rebates #bja4 ,medicare part ,b rebate by manufacturers 7a7 ,in general ,section #ahdg;,a of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7 is amended-- 7#a7 by redesignating subsection 7h7 as subsection 7i7 and by inserting after subsection 7g7 the following subsection3 7h7 ,rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation 7#a7 ,requirements 7,a7 ,secretarial provision of information ,not later than #f months after the end of each calendar quarter beginning on or after ,july #a1 #bjbc1 the ,secretary shall1 for each part ,b rebatable drug1 report to each manufacturer of such part ,b rebatable drug the following for such calendar quarter3 7i7 ,information on the total number of billing units of the billing and payment code described in subparagraph 7,a77i7 of paragraph 7#c7 with respect to such drug and calendar quarter4 7ii7 ,information on the amount 7if any7 of the excess average sales price increase described in subparagraph 7,a77ii7 of such paragraph for such drug and calendar quarter4 7iii7 ,the rebate amount specified under such paragraph for such part ,b rebatable drug and calendar quarter4 7,b7 ,manufacturer requirement ,for each calendar quarter beginning on or after ,july #a1 #bjbc1 the manufacturer of a part ,b rebatable drug shall1 for such drug1 not later than #cj days after the date of receipt from the ,secretary of the information described in subparagraph 7,a7 for such calendar quarter1 provide to the ,secretary a rebate that is equal to the amount specified in paragraph 7#c7 for such drug for such calendar quarter4 7#b7 ,part ,b rebatable drug defined 7,a7 ,in general ,in this subsection1 the term part ,b rebatable drug means a single source drug or biological 7as defined in subparagraph 7,d7 of subsection 7c77#f771 including a biosimilar biological product 7as defined in subparagraph 7,h7 of such subsection7 but excluding a qualifying biosimilar biological product 7as defined in subsection 7b77#h77;,b77iii771 that would be payable under this part if such drug were furnished to an individual enrolled under this part1 except such term shall not include such a drug or biological-- 7i7 if1 as determined by the ,secretary1 the average total allowed charges for such drug or biological under this part for a year per individual that uses such a drug or biological are less than1 subject to subparagraph 7,b71 #ajj2 or 7ii7 that is a vaccine described in subparagraph 7,a7 or 7,b7 of section #ahfa7s77#aj74 7,b7 ,increase ,the dollar amount applied under subparagraph 7,a77i7-- 7i7 for #bjbd1 shall be the dollar amount specified under such subparagraph for #bjbc1 increased by the percentage increase in the consumer price index for all urban consumers 7,united ,states city average7 for the #ab-month period ending with ,june of the previous year2 and 7ii7 for a subsequent year1 shall be the dollar amount specified in this clause 7or clause 7i77 for the previous year 7without application of subparagraph 7,c771 increased by the percentage increase in the consumer price index for all urban consumers 7,united ,states city average7 for the #ab-month period ending with ,june of the previous year4 7,c7 ,rounding ,any dollar amount determined under subparagraph 7,b7 that is not a multiple of #aj shall be rounded to the nearest multiple of #aj4 7#c7 ,rebate amount 7,a7 ,in general ,for purposes of paragraph 7#a71 the amount specified in this paragraph for a part ,b rebatable drug assigned to a billing and payment code for a calendar quarter is1 subject to subparagraphs 7,b7 and 7,g7 and paragraph 7#d71 the amount equal to the product of-- 7i7 the total number of billing units determined under subparagraph 7,b7 for the billing and payment code of such drug2 and 7ii7 the amount 7if any7 by which-- 7,i7 the amount equal to-- 7aa7 in the case of a part ,b rebatable drug described in paragraph 7#a77;,b7 of section #ahdg;,a7b71 #ajf percent of the amount determined under paragraph 7#d7 of such section for such drug during the calendar quarter2 or 7bb7 in the case of a part ,b rebatable drug described in paragraph 7#a77;,c7 of such section1 the payment amount under such paragraph for such drug during the calendar quarter2 exceeds 7,,ii7 the inflation-adjusted payment amount determined under subparagraph 7,c7 for such part ,b rebatable drug during the calendar quarter4 7,b7 ,total number of billing units ,for purposes of subparagraph 7,a77i71 the total number of billing units with respect to a part ,b rebatable drug is determined as follows3 7i7 ,determine the total number of units equal to-- 7,i7 the total number of units1 as reported under subsection 7c77#a77;,b7 for each ,national ,drug ,code of such drug during the calendar quarter that is two calendar quarters prior to the calendar quarter as described in subparagraph 7,a71 minus 7,,ii7 the total number of units with respect to each ,national ,drug ,code of such drug for which payment was made under a ,state plan under title ,,xix 7or waiver of such plan71 as reported by ,states under section #aibg7;b77#b77;,a7 for the rebate period that is the same calendar quarter as described in subclause 7,i74 7ii7 ,convert the units determined under clause 7i7 to billing units for the billing and payment code of such drug1 using a methodology similar to the methodology used under this section1 by dividing the units determined under clause 7i7 for each ,national ,drug ,code of such drug by the billing unit for the billing and payment code of such drug4 7iii7 ,compute the sum of the billing units for each ,national ,drug ,code of such drug in clause 7ii74 7,c7 ,determination of inflation-adjusted payment amount ,the inflation-adjusted payment amount determined under this subparagraph for a part ,b rebatable drug for a calendar quarter is-- 7i7 the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter 7as defined in subparagraph 7,d772 increased by 7ii7 the percentage by which the rebate period ,,cpi-,u 7as defined in subparagraph 7,f77 for the calendar quarter exceeds the benchmark period ,,cpi-,u 7as defined in subparagraph 7,e774 7,d7 ,payment amount benchmark quarter ,the term payment amount benchmark quarter means the calendar quarter immediately prior to the calendar quarter beginning ,october #a1 #bjba4 7,e7 ,benchmark period ,,cpi-,u ,the term benchmark period ,,cpi-,u means the consumer price index for all urban consumers 7,united ,states city average7 for the last month of the calendar quarter beginning ,october #a1 #bjba4 7,f7 ,rebate period ,,cpi-,u ,the term rebate period ,,cpi-,u means1 with respect to a calendar quarter described in subparagraph 7,c71 the greater of the benchmark period ,,cpi-,u and the consumer price index for all urban consumers 7,united ,states city average7 for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter4 7,g7 ,exemption for shortages and severe supply chain disruptions ,the ,secretary shall reduce or waive the amount under subparagraph 7,a7 with respect to a part ,b rebatable drug that is described as currently in shortage on the shortage list in effect under section #ejf;,e of the ,federal ,food1 ,drug1 and ,cosmetic ,act or in the case of a biosimilar biological product1 when the ,secretary determines there are severe supply chain disruptions4 7#d7 ,special treatment of certain drugs and exemption 7,a7 ,subsequently approved drugs ,in the case of a part ,b rebatable drug first approved or licensed by the ,food and ,drug ,administration after ,march #a1 #bjba1 clause 7i7 of paragraph 7#c77;,c7 shall be applied as if the term payment amount benchmark quarter were defined under paragraph 7#c77;,d7 as the third full calendar quarter after the day on which the drug was first marketed and clause 7ii7 of paragraph 7#c77;,c7 shall be applied as if the term benchmark period ,,cpi-,u were defined under paragraph 7#c77;,e7 as if the reference to the last month of the calendar quarter immediately prior to the calendar quarter beginning ,october #a1 #bjba under such paragraph were a reference to the first month of the first full calendar quarter after the day on which the drug was first marketed4 7,b7 ,timeline for provision of rebates for subsequently approved drugs ,in the case of a part ,b rebatable drug first approved or licensed by the ,food and ,drug ,administration after ,march #a1 #bjba1 paragraph 7#a77;,b7 shall be applied as if the reference to ,july #a1 #bjbc under such paragraph were a reference to the later of the #fth full calendar quarter after the day on which the drug was first marketed or ,july #a1 #bjbc4 7,c7 ,selected drugs ,in the case of a part ,b rebatable drug that is a selected drug 7as defined in section #aaib7;c77 for a price applicability period 7as defined in section #aaia7;b77#b771 in the case such drug is determined 7pursuant to such section #aaib7;c77 to no longer be a selected drug1 beginning the first calendar quarter after the price applicability period with respect to such drug1 clause 7i7 of paragraph 7#c77;,c7 shall be applied as if the term payment amount benchmark quarter were defined under paragraph 7#c77;,d7 as the calendar quarter beginning ,january #a of the last year beginning during such price applicability period with respect to such selected drug and clause 7ii7 of paragraph 7#c77;,c7 shall be applied as if the term benchmark period ,,cpi-,u were defined under paragraph 7#c77;,e7 as if the reference to the last month of the calendar quarter immediately prior to the calendar quarter beginning ,october #a1 #bjba under such paragraph were a reference to the ,march of the year preceding such last year4 7#e7 ,application to beneficiary coinsurance ,in the case of a part ,b rebatable drug1 if the payment amount described in paragraph 7#c77;,a77ii77,i7 7or1 in the case of a part ,b rebatable drug that is a selected drug 7as defined in section #aaib7;c771 the payment amount described in subsection 7b77#a77;,b7 for such drug7 for a calendar quarter exceeds the inflation adjusted payment for such quarter-- 7,a7 in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished1 the computation of such coinsurance shall be equal to #bj percent of the inflation-adjusted payment amount determined under paragraph 7#c77;,c7 for such part ,b rebatable drug2 and 7,b7 the amount of such coinsurance for such calendar quarter1 as computed under subparagraph 7,a71 shall be applied as a percent1 as determined by the ,secretary1 to the payment amount that would otherwise apply under subparagraph 7,b7 or 7,c7 of subsection 7b77#a74 7#f7 ,rebate deposits ,amounts paid as rebates under paragraph 7#a77;,b7 shall be deposited into the ,federal ,supplementary ,medical ,insurance ,trust ,fund established under section #ahda4 7#g7 ,civil money penalty ,if a manufacturer of a part ,b rebatable drug has failed to comply with the requirements under paragraph 7#a77;,b7 for such drug for a calendar quarter1 the manufacturer shall be subject to1 in accordance with a process established by the ,secretary pursuant to regulations1 a civil money penalty in an amount equal to at least #abe percent of the amount specified in paragraph 7#c7 for such drug for such calendar quarter4 ,the provisions of section #aabh;,a 7other than subsections 7a7 7with respect to amounts of penalties or additional assessments7 and 7b77 shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a7a74 2 and 7#b7 in subsection 7i71 as redesignated by paragraph 7#a7-- 7,a7 in paragraph 7#d71 by striking at the end and2 7,b7 in paragraph 7#e71 by striking at the end the period and inserting a semicolon2 and 7,c7 by adding at the end the following new paragraphs3 7#f7 the determination of units under subsection 7h72 7#g7 the determination of whether a drug is a part ,b rebatable drug under subsection 7h72 7#h7 the calculation of the rebate amount under subsection 7h72 7#i7 the computation of coinsurance under subsection 7h77#e72 and 7#aj7 the computation of amounts paid under section #ahcc7;a77#a77;,,ee74 4 7b7 ,amounts payable2 cost-,sharing ,section #ahcc of the ,social ,security ,act 7#db ,u4,s4,c4 #aciel7 is amended-- 7#a7 in subsection 7a77#a7-- 7,a7 in subparagraph 7,g71 by inserting 1 subject to subsection 7i77#i71 after the amounts paid2 7,b7 in subparagraph 7,s71 by striking with respect to and inserting subject to subparagraph 7,,ee71 with respect to2 7,c7 by striking and 7,,dd7 and inserting 7,,dd72 and 7,d7 by inserting before the semicolon at the end the following3 1 and 7,,ee7 with respect to a part ,b rebatable drug 7as defined in paragraph 7#b7 of section #ahdg;,a7h77 for which the payment amount for a calendar quarter under paragraph 7#c77;,a77ii77,i7 of such section 7or1 in the case of a part ,b rebatable drug that is a selected drug 7as defined in section #aaib7;c77 for which1 the payment amount described in section #ahdg;,a7b77#a77;,b77 for such drug for such quarter exceeds the inflation-adjusted payment under paragraph 7#c77;,a77ii77,,ii7 of such section for such quarter1 the amounts paid shall be equal to the percent of the payment amount under paragraph 7#c77;,a77ii77,i7 of such section or section #ahdg;,a7b77#a77;,b71 as applicable1 that equals the difference between 7i7 #ajj percent1 and 7ii7 the percent applied under section #ahdg;,a7h77#e77;,b72 7#b7 in subsection 7i71 by adding at the end the following new paragraph3 7#i7 ,in the case of a part ,b rebatable drug 7as defined in paragraph 7#b7 of section #ahdg;,a7h77 for which payment under this subsection is not packaged into a payment for a service furnished on or after ,july #a1 #bjbc1 under the revised payment system under this subsection1 in lieu of calculation of coinsurance and the amount of payment otherwise applicable under this subsection1 the provisions of section #ahdg;,a7h77#e7 and paragraph 7#a77;,,ee7 of subsection 7a71 shall1 as determined appropriate by the ,secretary1 apply under this subsection in the same manner as such provisions of section #ahdg;,a7h77#e7 and subsection 7a7 apply under such section and subsection4 2 and 7#c7 in subsection 7t77#h71 by adding at the end the following new subparagraph3 7,f7 ,part ,b rebatable drugs ,in the case of a part ,b rebatable drug 7as defined in paragraph 7#b7 of section #ahdg;,a7h71 except if such drug does not have a copayment amount as a result of application of subparagraph 7,e77 for which payment under this part is not packaged into a payment for a covered ,,opd service 7or group of services7 furnished on or after ,july #a1 #bjbc1 and the payment for such drug under this subsection is the same as the amount for a calendar quarter under paragraph 7#c77;,a77ii77,i7 of section #ahdg;,a7h71 under the system under this subsection1 in lieu of calculation of the copayment amount and the amount of payment otherwise applicable under this subsection 7other than the application of the limitation described in subparagraph 7,c771 the provisions of section #ahdg;,a7h77#e7 and paragraph 7#a77;,,ee7 of subsection 7a71 shall1 as determined appropriate by the ,secretary1 apply under this subsection in the same manner as such provisions of section #ahdg;,a7h77#e7 and subsection 7a7 apply under such section and subsection4 4 7c7 ,conforming amendments 7#a7 ,to part ,b ,,asp calculation ,section #ahdg;,a7c77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#c77 is amended by inserting subsection 7h7 or before section #aibg4 7#b7 ,excluding part ,b drug inflation rebate from best price ,section #aibg7;c77#a77;,c77ii77,i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;c77#a77;,c77ii77,i77 is amended by inserting or section #ahdg;,a7h7 after this section4 7#c7 ,coordination with ,medicaid rebate information disclosure ,section #aibg7;b77#c77;,d77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;b77#c77;,d77i77 is amended by inserting and the rebate after the payment amount4 7#d7 ,excluding part ,b drug inflation rebates from average manufacturer price ,section #aibg7k77#a77;,b77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#a77;,b77i771 as previously amended1 is further amended-- 7,a7 in subclause 7,,iv71 by striking and2 7,b7 in subclause 7,v71 by striking the period at the end and inserting a semicolon2 and 7,c7 by adding at the end the following new subclause3 7,,vi7 rebates paid by manufacturers under section #ahdg;,a7h72 and 4 7d7 ,funding ,in addition to amounts otherwise available1 there are appropriated to the ,centers for ,medicare ,medicaid ,services1 out of any money in the ,treasury not otherwise appropriated1 #ab1ejj1jjj for fiscal year #bjbb and #g1ejj1jjj for each of fiscal years #bjbc through #bjca1 to remain available until expended1 to carry out the provisions of1 including the amendments made by1 this section4 #bjb4 ,medicare part ,d rebate by manufacturers 7a7 ,in general ,part ,d of title ,,xviii of the ,social ,security ,act is amended by inserting after section #ahfj;,d-#ad;,a 7#db ,u4,s4,c4 #aciew-#aad;a7 the following new section3 #ahfj;,d-#ad;,b4 ,manufacturer rebate for certain drugs with prices increasing faster than inflation 7a7 ,requirements 7#a7 ,secretarial provision of information ,not later than #i months after the end of each applicable year 7as defined in subsection 7g77#g771 subject to paragraph 7#c71 the ,secretary shall1 for each part ,d rebatable drug1 report to each manufacturer of such part ,d rebatable drug the following for such year3 7,a7 ,the amount 7if any7 of the excess annual manufacturer price increase described in subsection 7b77#a77;,a77ii7 for each dosage form and strength with respect to such drug and year4 7,b7 ,the rebate amount specified under subsection 7b7 for each dosage form and strength with respect to such drug and year4 7#b7 ,manufacturer requirements ,for each applicable year1 the manufacturer of a part ,d rebatable drug1 for each dosage form and strength with respect to such drug1 not later than #cj days after the date of receipt from the ,secretary of the information described in paragraph 7#a7 for such year1 shall provide to the ,secretary a rebate that is equal to the amount specified in subsection 7b7 for such dosage form and strength with respect to such drug for such year4 7#c7 ,transition rule for reporting ,the ,secretary may1 for each rebatable covered part ,d drug1 delay the timeframe for reporting the information and rebate amount described in subparagraphs 7,a7 and 7,b7 of such paragraph for the applicable year of #bjbc until not later than ,september #cj1 #bjbe4 7b7 ,rebate amount 7#a7 ,in general 7,a7 ,calculation ,for purposes of this section1 the amount specified in this subsection for a dosage form and strength with respect to a part ,d rebatable drug and applicable year is1 subject to subparagraph 7,c71 paragraph 7#e77;,b71 and paragraph 7#f71 the amount equal to the product of-- 7i7 subject to subparagraph 7,b7 of this paragraph1 the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such part ,d rebatable drug1 as reported by the manufacturer of such drug under section #aibg for each month1 with respect to such year2 and 7ii7 the amount 7if any7 by which-- 7,i7 the annual manufacturer price 7as determined in paragraph 7#b77 paid for such dosage form and strength with respect to such part ,d rebatable drug for the year2 exceeds 7,,ii7 the inflation-adjusted payment amount determined under paragraph 7#c7 for such dosage form and strength with respect to such part ,d rebatable drug for the year4 7,b7 ,excluded units ,for purposes of subparagraph 7,a77i71 the ,secretary shall exclude from the total number of units for a dosage form and strength with respect to a part ,d rebatable drug1 with respect to an applicable year1 the following3 7i7 ,units of each dosage form and strength of such part ,d rebatable drug for which payment was made under a ,state plan under title ,,xix 7or waiver of such plan71 as reported by ,states under section #aibg7;b77#b77;,a74 7ii7 ,units of each dosage form and strength of such part ,d rebatable drug for which a rebate is paid under section #ahdg;,a7h74 7,c7 ,exemption for shortages and severe supply chain disruptions ,the ,secretary shall reduce or waive the amount under subparagraph 7,a7 with respect to a part ,d rebatable drug that is described as currently in shortage on the shortage list in effect under section #ejf;,e of the ,federal ,food1 ,drug1 and ,cosmetic ,act or in the case of a generic drug1 when the ,secretary determines there are severe supply chain disruptions4 7#b7 ,determination of annual manufacturer price ,the annual manufacturer price determined under this paragraph for a dosage form and strength1 with respect to a part ,d rebatable drug and an applicable year1 is the sum of the products of-- 7,a7 the average manufacturer price 7as defined in subsection 7g77#f77 of such dosage form and strength1 as calculated for a unit of such drug1 with respect to each of the calendar quarters of such year2 and 7,b7 the ratio of-- 7i7 the total number of units of such dosage form and strength reported under section #aibg with respect to each such calendar quarter of such year2 to 7ii7 the total number of units of such dosage form and strength reported under section #aibg with respect to such year1 as determined by the ,secretary4 7#c7 ,determination of inflation-adjusted payment amount ,the inflation-adjusted payment amount determined under this paragraph for a dosage form and strength with respect to a part ,d rebatable drug for an applicable year1 subject to paragraph 7#e71 is-- 7,a7 the benchmark year manufacturer price determined under paragraph 7#d7 for such dosage form and strength with respect to such drug and year2 increased by 7,b7 the percentage by which the applicable year ,,cpi-,u 7as defined in subsection 7g77#e77 for the year exceeds the benchmark period ,,cpi-,u 7as defined in subsection 7g77#d774 7#d7 ,determination of benchmark year manufacturer price ,the benchmark year manufacturer price determined under this paragraph for a dosage form and strength1 with respect to a part ,d rebatable drug and an applicable year1 is the sum of the products of-- 7,a7 the average manufacturer price 7as defined in subsection 7g77#f77 of such dosage form and strength1 as calculated for a unit of such drug1 with respect to each of the calendar quarters of the payment amount benchmark year 7as defined in subsection 7g77#c772 and 7,b7 the ratio of-- 7i7 the total number of units reported under section #aibg of such dosage form and strength with respect to each such calendar quarter of such payment amount benchmark year2 to 7ii7 the total number of units reported under section #aibg of such dosage form and strength with respect to such payment amount benchmark year4 7#e7 ,special treatment of certain drugs and exemption 7,a7 ,subsequently approved drugs ,in the case of a part ,d rebatable drug first approved or licensed by the ,food and ,drug ,administration after ,october #a1 #bjba1 subparagraphs 7,a7 and 7,b7 of paragraph 7#d7 shall be applied as if the term payment amount benchmark year were defined under subsection 7g77#c7 as the first calendar year beginning after the day on which the drug was first marketed by any manufacturer and subparagraph 7,b7 of paragraph 7#c7 shall be applied as if the term benchmark period ,,cpi-,u were defined under subsection 7g77#d7 as if the reference to the month immediately prior to ,october #bjba under such subsection were a reference to ,january of the first year beginning after the date on which the drug was first marketed by any manufacturer4 7,b7 ,treatment of new formulations 7i7 ,in general ,in the case of a part ,d rebatable drug that is a line extension of a part ,d rebatable drug that is an oral solid dosage form1 the ,secretary shall establish a formula for determining the rebate amount under paragraph 7#a7 and the inflation adjusted payment amount under paragraph 7#c7 with respect to such part ,d rebatable drug and an applicable year1 consistent with the formula applied under subsection 7c77#b77;,c7 of section #aibg for determining a rebate obligation for a rebate period under such section4 7ii7 ,line extension defined ,in this subparagraph1 the term line extension means1 with respect to a part ,d rebatable drug1 a new formulation of the drug1 such as an extended release formulation1 but does not include an abuse-deterrent formulation of the drug 7as determined by the ,secretary71 regardless of whether such abuse-deterrent formulation is an extended release formulation4 7,c7 ,selected drugs ,in the case of a part ,d rebatable drug that is a selected drug 7as defined in section #aaib7;c77 for a price applicability period 7as defined in section #aaia7;b77#b771 in the case such drug is determined 7pursuant to such section #aaib7;c77 to no longer be a selected drug1 for each applicable year beginning after the price applicability period with respect to such drug1 subparagraphs 7,a7 and 7,b7 of paragraph 7#d7 shall be applied as if the term payment amount benchmark year were defined under subsection 7g77#c7 as the last year beginning during such price applicability period with respect to such selected drug and subparagraph 7,b7 of paragraph 7#c7 shall be applied as if the term benchmark period ,,cpi-,u were defined under subsection 7g77#d7 as if the reference to the month immediately prior to ,october #a1 #bjba under such subsection were a reference to ,january of the last year beginning during such price applicability period with respect to such drug4 7#f7 ,reconciliation in case of revised ,,amp reports ,the ,secretary shall provide for a method and process under which1 in the case of a manufacturer of a part ,d rebatable drug that submits revisions to information submitted under section #aibg by the manufacturer with respect to such drug1 the ,secretary determines1 pursuant to such revisions1 adjustments1 if any1 to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part ,d rebatable drug and an applicable year and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection4 ,any identified underpayment shall be rectified by the manufacturer not later than #cj days after the date of receipt from the ,secretary of information on such underpayment4 7c7 ,rebate deposits ,amounts paid as rebates under subsection 7b7 shall be deposited into the ,medicare ,prescription ,drug ,account in the ,federal ,supplementary ,medical ,insurance ,trust ,fund established under section #ahda4 7d7 ,information ,for purposes of carrying out this section1 the ,secretary shall use information submitted by manufacturers under section #aibg7;b77#c7 and information submitted by ,states under section #aibg7;b77#b77;,a74 7e7 ,civil money penalty ,if a manufacturer of a part ,d rebatable drug has failed to comply with the requirement under subsection 7a77#b7 with respect to such drug for an applicable year1 the manufacturer shall be subject to1 in accordance with a process established by the ,secretary pursuant to regulations1 a civil money penalty in an amount equal to #abe percent of the amount specified in subsection 7b7 for such drug for such year4 ,the provisions of section #aabh;,a 7other than subsections 7a7 7with respect to amounts of penalties or additional assessments7 and 7b77 shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a7a74 7f7 ,no administrative or judicial review ,there shall be no administrative or judicial review of the following3 7#a7 ,the determination of units under this section4 7#b7 ,the determination of whether a drug is a part ,d rebatable drug under this section4 7#c7 ,the calculation of the rebate amount under this section4 7g7 ,definitions ,in this section3 7#a7 ,part ,d rebatable drug 7,a7 ,in general ,the term part ,d rebatable drug means a drug or biological that would 7without application of this section7 be a covered part ,d drug1 except such term shall1 with respect to an applicable year1 not include such a drug or biological if the average annual total cost under this part for such year per individual who uses such a drug or biological1 as determined by the ,secretary1 is less than1 subject to subparagraph 7,b71 #ajj1 as determined by the ,secretary using the most recent data available or1 if data is not available1 as estimated by the ,secretary4 7,b7 ,increase ,the dollar amount applied under subparagraph 7,a7-- 7i7 for #bjbd1 shall be the dollar amount specified under such subparagraph for #bjbc1 increased by the percentage increase in the consumer price index for all urban consumers 7,united ,states city average7 for the #ab-month period beginning with ,january of #bjbc2 and 7ii7 for a subsequent year1 shall be the dollar amount specified in this subparagraph for the previous year1 increased by the percentage increase in the consumer price index for all urban consumers 7,united ,states city average7 for the #ab-month period beginning with ,january of the previous year4 ,any dollar amount specified under this subparagraph that is not a multiple of #aj shall be rounded to the nearest multiple of #aj4 7#b7 ,unit ,the term unit means1 with respect to a part ,d rebatable drug1 the lowest dispensable amount 7such as a capsule or tablet1 milligram of molecules1 or grams7 of the part ,d rebatable drug1 as reported under section #aibg4 7#c7 ,payment amount benchmark year ,the term payment amount benchmark year means the year ending in the month immediately prior to ,october #a1 #bjba4 7#d7 ,benchmark period ,,cpi-,u ,the term benchmark period ,,cpi-,u means the consumer price index for all urban consumers 7,united ,states city average7 for the month immediately prior to ,october #bjba4 7#e7 ,applicable year ,,cpi-,u ,the term applicable year ,,cpi-,u means1 with respect to an applicable year1 the consumer price index for all urban consumers 7,united ,states city average7 for ,january of such year4 7#f7 ,average manufacturer price ,the term average manufacturer price has the meaning1 with respect to a part ,d rebatable drug of a manufacturer1 given such term in section #aibg7k77#a71 with respect to a covered outpatient drug of a manufacturer for a rebate period under section #aibg4 7#g7 ,applicable year ,the term applicable year means a calendar year beginning with #bjbc4 7h7 ,implementation for #bjbc and #bjbd ,notwithstanding any other provision of this section1 the ,secretary shall implement this section for #bjbc and #bjbd by program instruction or otherwise4 4 7b7 ,conforming amendments 7#a7 ,to part ,b ,,asp calculation ,section #ahdg;,a7c77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#c771 as amended by section #bja7;c77#a71 is further amended by striking subsection 7h7 or section #aibg and inserting subsection 7h71 section #aibg1 or section #ahfj;,d-#ad;,b4 7#b7 ,excluding part ,d drug inflation rebate from best price ,section #aibg7;c77#a77;,c77ii77,i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;c77#a77;,c77ii77,i771 as amended by section #bja7;c77#b71 is further amended by striking or section #ahdg;,a7h7 and inserting 1 section #ahdg;,a7h71 or section #ahfj;,d-#ad;,b4 7#c7 ,coordination with ,medicaid rebate information disclosure ,section #aibg7;b77#c77;,d77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;b77#c77;,d77i771 as amended by section #bja7;c77#c71 is further amended by striking or to carry out section #ahdg;,b and inserting or to carry out section #ahdg;,b or section #ahfj;,d-#ad;,b4 7#d7 ,excluding part ,d drug inflation rebates from average manufacturer price ,section #aibg7k77#a77;,b77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#a77;,b77i771 as previously amended1 is further amended by adding at the end the following new subclause3 7,,vii7 rebates paid by manufacturers under section #ahfj;,d-#ad;,b4 4 7c7 ,funding ,in addition to amounts otherwise available1 there are appropriated to the ,centers for ,medicare ,medicaid ,services1 out of any money in the ,treasury not otherwise appropriated1 #ab1ejj1jjj for fiscal year #bjbb and #g1ejj1jjj for each of fiscal years #bjbc through #bjca1 to remain available until expended1 to carry out the provisions of1 including the amendments made by1 this section4 ,,iii ,part ,d ,improvements and ,maximum ,out-of-,pocket ,cap for ,medicare ,beneficiaries #cja4 ,medicare part ,d benefit redesign 7a7 ,benefit structure redesign ,section #ahfj;,d-#b7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;b77 is amended-- 7#a7 in paragraph 7#b7-- 7,a7 in subparagraph 7,a71 in the matter preceding clause 7i71 by inserting for a year preceding #bjbd and for costs above the annual deductible specified in paragraph 7#a7 and up to the annual out-of-pocket threshold specified in paragraph 7#d77;,b7 for #bjbd and each subsequent year after paragraph 7#c72 7,b7 in subparagraph 7,c7-- 7i7 in clause 7i71 in the matter preceding subclause 7,i71 by inserting for a year preceding #bjbd1 after paragraph 7#d712 and 7ii7 in clause 7ii77,,iii71 by striking and each subsequent year and inserting through #bjbc2 and 7,c7 in subparagraph 7,d7-- 7i7 in clause 7i7-- 7,i7 in the matter preceding subclause 7,i71 by inserting for a year preceding #bjbd1 after paragraph 7#d712 and 7,,ii7 in subclause 7,i77bb71 by striking a year after #bjah and inserting each of years #bjai through #bjbc2 and 7ii7 in clause 7ii77,v71 by striking #bjai and each subsequent year and inserting each of years #bjai through #bjbc2 7#b7 in paragraph 7#c77;,a7-- 7,a7 in the matter preceding clause 7i71 by inserting for a year preceding #bjbd1 after and 7#d712 and 7,b7 in clause 7ii71 by striking for a subsequent year and inserting for each of years #bjjg through #bjbc2 and 7#c7 in paragraph 7#d7-- 7,a7 in subparagraph 7,a7-- 7i7 in clause 7i7-- 7,i7 by redesignating subclauses 7,i7 and 7,,ii7 as items 7aa7 and 7bb71 respectively1 and moving the margin of each such redesignated item #b ems to the right2 7,,ii7 in the matter preceding item 7aa71 as redesignated by subclause 7,i71 by striking is equal to the greater of-- and inserting 8is equal to-- 7,i7 for a year preceding #bjbd1 the greater of-- 2 7,,iii7 by striking the period at the end of item 7bb71 as redesignated by subclause 7,i71 and inserting 2 and2 and 7,,iv7 by adding at the end the following3 7,,ii7 for #bjbd and each succeeding year1 #j4 2 and 7ii7 in clause 7ii7-- 7,i7 by striking clause 7i77,i7 and inserting clause 7i77,i77aa72 and 7,,ii7 by adding at the end the following new sentence3 ,the ,secretary shall continue to calculate the dollar amounts specified in clause 7i77,i77aa71 including with the adjustment under this clause1 after #bjbc for purposes of section #ahfj;,d-#ad7;a77#a77;,d77iii742 7,b7 in subparagraph 7,b7-- 7i7 in clause 7i7-- 7,i7 in subclause 7,v71 by striking or at the end2 7,,ii7 in subclause 7,,vi7-- 7aa7 by striking for a subsequent year and inserting for each of years #bjba through #bjbc2 and 7bb7 by striking the period at the end and inserting a semicolon2 and 7,,iii7 by adding at the end the following new subclauses3 7,,vii7 for #bjbd1 is equal to #b1jjj2 or 7,,viii7 for a subsequent year1 is equal to the amount specified in this subparagraph for the previous year1 increased by the annual percentage increase described in paragraph 7#f7 for the year involved4 2 and 7ii7 in clause 7ii71 by striking clause 7i77,,ii7 and inserting clause 7i72 7,c7 in subparagraph 7,c77i71 by striking and for amounts and inserting and1 for a year preceding #bjbd1 for amounts2 and 7,d7 in subparagraph 7,e71 by striking ,in applying and inserting ,for each of years #bjaa through #bjbc1 in applying4 7b7 ,reinsurance payment amount ,section #ahfj;,d-#ae7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aae7;b77 is amended-- 7#a7 in paragraph 7#a7-- 7,a7 by striking equal to #hj percent and inserting 8equal to-- 7,a7 for a year preceding #bjbd1 #hj percent 2 7,b7 in subparagraph 7,a71 as added by subparagraph 7,a71 by striking the period at the end and inserting 2 and2 and 7,c7 by adding at the end the following new subparagraph3 7,b7 for #bjbd and each subsequent year1 the sum of-- 7i7 an amount equal to #bj percent of such allowable reinsurance costs attributable to that portion of gross prescription drug costs as specified in paragraph 7#c7 incurred in the coverage year after such individual has incurred costs that exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b7 with respect to applicable drugs 7as defined in section #ahfj;,d-#ad;,c7g77#b772 and 7ii7 an amount equal to #dj percent of such allowable reinsurance costs attributable to that portion of gross prescription drug costs as specified in paragraph 7#c7 incurred in the coverage year after such individual has incurred costs that exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b7 with respect to covered part ,d drugs that are not applicable drugs 7as so defined74 2 7#b7 in paragraph 7#b7-- 7,a7 by striking ,,costs4--,for purposes and inserting ,costs4-- 7,a7 ,in general ,subject to subparagraph 7,b71 for purposes 2 and 7,b7 by adding at the end the following new subparagraph3 7,b7 ,inclusion of manufacturer discounts on applicable drugs ,for purposes of applying subparagraph 7,a71 the term allowable reinsurance costs shall include the portion of the negotiated price 7as defined in section #ahfj;,d-#ad;,c7g77#f77 of an applicable drug 7as defined in section #ahfj;,d-#ad;,c7g77#b77 that was paid by a manufacturer under the manufacturer discount program under section #ahfj;,d-#ad;,c4 2 and 7#c7 in paragraph 7#c7-- 7,a7 in the first sentence1 by striking ,for purposes and inserting ,subject to paragraph 7#b77;,b71 for purposes2 and 7,b7 in the second sentence1 by inserting 7or1 with respect to #bjbd and subsequent years1 in the case of an applicable drug1 as defined in section #ahfj;,d-#ad;,c7g77#b71 by a manufacturer7 after by the individual or under the plan4 7c7 ,reduced cost-,sharing2 beneficiary premium percentage 7#a7 ,cost-sharing 7,a7 ,in general ,section #ahfj;,d-#b7;b77#b77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;b77#b77;,a77 is amended-- 7i7 in the subparagraph header1 by striking #be percent coinsurance and inserting ,coinsurance2 7ii7 in clause 7i71 by inserting 7or1 for #bjbd and each subsequent year1 #bc percent7 after #be percent2 and 7iii7 in clause 7ii71 by inserting 7or1 for #bjbd and each subsequent year1 #bc percent7 after #be percent4 7,b7 ,conforming amendment ,section #ahfj;,d-#ad7;a77#b77;,d7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aad7;a77#b77;,d77 is amended by inserting 7or1 for #bjbd and each subsequent year1 instead of coinsurance of #bc percent7 after instead of coinsurance of #be percent4 7#b7 ,beneficiary premium percentage 7,a7 ,in general ,section #ahfj;,d-#ac7;a77#c77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aac7;a77#c77;,a77 is amended by inserting 7or1 for #bjbd and each subsequent year1 #bc4e percent7 after #be4e percent4 7,b7 ,conforming amendments 7i7 ,section #ahfj;,d-#aa7;g77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;g77#f77 is amended by inserting 7or1 for #bjbd and each subsequent year1 #bc4e percent7 after #be4e percent4 7ii7 ,section #ahfj;,d-#ac7;a77#g77;,b77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aac7;a77#g77;,b77i77 is amended-- 7,i7 in subclause 7,i71 by inserting 7or1 for #bjbd and each subsequent year1 #bc4e percent7 after #be4e percent2 and 7,,ii7 in subclause 7,,ii71 by inserting 7or1 for #bjbd and each subsequent year1 #bc4e percent7 after #be4e percent4 7iii7 ,section #ahfj;,d-#ae7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aae7;a77 is amended by inserting 7or1 for #bjbd and each subsequent year1 #gf4e percent7 after #gd4e percent4 7d7 ,manufacturer discount program 7#a7 ,in general ,part ,d of title ,,xviii of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aja through #db ,u4,s4,c4 #aciew-#aec71 as amended by section #bjb1 is further amended by inserting after section #ahfj;,d-#ad;,b the following new sections3 #ahfj;,d-#ad;,c4 ,manufacturer discount program 7a7 ,establishment ,the ,secretary shall establish a manufacturer discount program 7in this section referred to as the program74 ,under the program1 the ,secretary shall enter into agreements described in subsection 7b7 with manufacturers and provide for the performance of the duties described in subsection 7c74 ,the ,secretary shall establish a model agreement for use under the program by not later than ,january #a1 #bjbc1 in consultation with manufacturers1 and allow for comment on such model agreement4 7b7 ,terms of agreement 7#a7 ,in general 7,a7 ,agreement ,an agreement under this section shall require the manufacturer to provide1 in accordance with this section1 discounted prices for applicable drugs of the manufacturer that are dispensed to applicable beneficiaries on or after ,january #a1 #bjbd4 7,b7 ,clarification ,nothing in this section shall be construed as affecting-- 7i7 the application of a coinsurance of #bc percent of the negotiated price1 as applied under paragraph 7#b77;,a7 of section #ahfj;,d-#b7;b71 for costs described in such paragraph2 or 7ii7 the application of the copayment amount described in paragraph 7#d77;,a7 of such section1 with respect to costs described in such paragraph4 7,c7 ,timing of agreement 7i7 ,special rule for #bjbd ,in order for an agreement with a manufacturer to be in effect under this section with respect to the period beginning on ,january #a1 #bjbd1 and ending on ,december #ca1 #bjbd1 the manufacturer shall enter into such agreement not later than #cj days after the date of the establishment of a model agreement under subsection 7a74 7ii7 #bjbe and subsequent years ,in order for an agreement with a manufacturer to be in effect under this section with respect to plan year #bjbe or a subsequent plan year1 the manufacturer shall enter into such agreement not later than a calendar quarter or semi-annual deadline established by the ,secretary4 7#b7 ,provision of appropriate data ,each manufacturer with an agreement in effect under this section shall collect and have available appropriate data1 as determined by the ,secretary1 to ensure that it can demonstrate to the ,secretary compliance with the requirements under the program4 7#c7 ,compliance with requirements for administration of program ,each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the ,secretary or a third party with a contract under subsection 7d77#c71 as applicable1 for purposes of administering the program1 including any determination under subparagraph 7,a7 of subsection 7c77#a7 or procedures established under such subsection 7c77#a74 7#d7 ,length of agreement 7,a7 ,in general ,an agreement under this section shall be effective for an initial period of not less than #ab months and shall be automatically renewed for a period of not less than #a year unless terminated under subparagraph 7,b74 7,b7 ,termination 7i7 ,by the ,secretary ,the ,secretary shall provide for termination of an agreement under this section for a knowing and willful violation of the requirements of the agreement or other good cause shown4 ,such termination shall not be effective earlier than #cj days after the date of notice to the manufacturer of such termination4 ,the ,secretary shall provide1 upon request1 a manufacturer with a hearing concerning such a termination1 and such hearing shall take place prior to the effective date of the termination with sufficient time for such effective date to be repealed if the ,secretary determines appropriate4 7ii7 ,by a manufacturer ,a manufacturer may terminate an agreement under this section for any reason4 ,any such termination shall be effective1 with respect to a plan year-- 7,i7 if the termination occurs before ,january #ca of a plan year1 as of the day after the end of the plan year2 and 7,,ii7 if the termination occurs on or after ,january #ca of a plan year1 as of the day after the end of the succeeding plan year4 7iii7 ,effectiveness of termination ,any termination under this subparagraph shall not affect discounts for applicable drugs of the manufacturer that are due under the agreement before the effective date of its termination4 7iv7 ,notice to third party ,the ,secretary shall provide notice of such termination to a third party with a contract under subsection 7d77#c7 within not less than #cj days before the effective date of such termination4 7c7 ,duties described ,the duties described in this subsection are the following3 7#a7 ,administration of program ,administering the program1 including-- 7,a7 the determination of the amount of the discounted price of an applicable drug of a manufacturer2 7,b7 the establishment of procedures to ensure that1 not later than the applicable number of calendar days after the dispensing of an applicable drug by a pharmacy or mail order service1 the pharmacy or mail order service is reimbursed for an amount equal to the difference between-- 7i7 the negotiated price of the applicable drug2 and 7ii7 the discounted price of the applicable drug2 7,c7 the establishment of procedures to ensure that the discounted price for an applicable drug under this section is applied before any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of applicable beneficiaries as specified by the ,secretary2 and 7,d7 providing a reasonable dispute resolution mechanism to resolve disagreements between manufacturers1 applicable beneficiaries1 and the third party with a contract under subsection 7d77#c74 7#b7 ,monitoring compliance 7,a7 ,in general ,the ,secretary shall monitor compliance by a manufacturer with the terms of an agreement under this section4 7,b7 ,notification ,if a third party with a contract under subsection 7d77#c7 determines that the manufacturer is not in compliance with such agreement1 the third party shall notify the ,secretary of such noncompliance for appropriate enforcement under subsection 7e74 7#c7 ,collection of data from prescription drug plans and ,,ma-,,pd plans ,the ,secretary may collect appropriate data from prescription drug plans and ,,ma-,,pd plans in a timeframe that allows for discounted prices to be provided for applicable drugs under this section4 7d7 ,administration 7#a7 ,in general ,subject to paragraph 7#b71 the ,secretary shall provide for the implementation of this section1 including the performance of the duties described in subsection 7c74 7#b7 ,limitation ,in providing for the implementation of this section1 the ,secretary shall not receive or distribute any funds of a manufacturer under the program4 7#c7 ,contract with third parties ,the ,secretary shall enter into a contract with #a or more third parties to administer the requirements established by the ,secretary in order to carry out this section4 ,at a minimum1 the contract with a third party under the preceding sentence shall require that the third party-- 7,a7 receive and transmit information between the ,secretary1 manufacturers1 and other individuals or entities the ,secretary determines appropriate2 7,b7 receive1 distribute1 or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this section2 7,c7 provide adequate and timely information to manufacturers1 consistent with the agreement with the manufacturer under this section1 as necessary for the manufacturer to fulfill its obligations under this section2 and 7,d7 permit manufacturers to conduct periodic audits1 directly or through contracts1 of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program4 7#d7 ,performance requirements ,the ,secretary shall establish performance requirements for a third party with a contract under paragraph 7#c7 and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this section4 7#e7 ,implementation ,the ,secretary shall implement the program under this section for #bjbd and #bjbe by program instruction or otherwise4 7e7 ,enforcement 7#a7 ,audits ,each manufacturer with an agreement in effect under this section shall be subject to periodic audit by the ,secretary4 7#b7 ,civil money penalty 7,a7 ,in general ,a manufacturer that fails to provide discounted prices for applicable drugs of the manufacturer dispensed to applicable beneficiaries in accordance with such agreement shall be subject to a civil money penalty for each such failure in an amount the ,secretary determines is equal to the sum of-- 7i7 the amount that the manufacturer would have paid with respect to such discounts under the agreement1 which will then be used to pay the discounts which the manufacturer had failed to provide2 and 7ii7 #be percent of such amount4 7,b7 ,application ,the provisions of section #aabh;,a 7other than subsections 7a7 and 7b77 shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a7a74 7f7 ,clarification regarding availability of other covered part ,d drugs ,nothing in this section shall prevent an applicable beneficiary from purchasing a covered part ,d drug that is not an applicable drug 7including a generic drug or a drug that is not on the formulary of the prescription drug plan or ,,ma-,,pd plan that the applicable beneficiary is enrolled in74 7g7 ,definitions ,in this section3 7#a7 ,applicable beneficiary ,the term applicable beneficiary means an individual who1 on the date of dispensing a covered part ,d drug-- 7,a7 is enrolled in a prescription drug plan or an ,,ma-,,pd plan2 7,b7 is not enrolled in a qualified retiree prescription drug plan2 and 7,c7 has incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c7 as if clause 7iii7 of such section included a reference to costs reimbursed through insurance1 a group health plan1 or certain other third-party payment arrangements1 for covered part ,d drugs in the year that exceed-- 7i7 in the case of an individual not described in clause 7ii7 or 7iii71 the annual deductible for such year1 as specified in section #ahfj;,d-#b7;b77#a72 7ii7 in the case of a subsidy eligible individual described in section #ahfj;,d-#ad7;a77#a71 the annual deductible for such year1 as specified in subparagraph 7,b7 of such section2 and 7iii7 in the case of a subsidy eligible individual described in section #ahfj;,d-#ad7;a77#b71 the annual deductible for such year1 as specified in subparagraph 7,b7 of such section4 7#b7 ,applicable drug ,the term applicable drug1 with respect to an applicable beneficiary-- 7,a7 means a covered part ,d drug-- 7i7 approved under a new drug application under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or1 in the case of a biologic product1 licensed under section #cea of the ,public ,health ,service ,act2 and 7ii7 7,i7 if the ,,pdp sponsor of the prescription drug plan or the ,,ma organization offering the ,,ma-,,pd plan uses a formulary1 which is on the formulary of the prescription drug plan or ,,ma-,,pd plan that the applicable beneficiary is enrolled in2 7,,ii7 if the ,,pdp sponsor of the prescription drug plan or the ,,ma organization offering the ,,ma-,,pd plan does not use a formulary1 for which benefits are available under the prescription drug plan or ,,ma-,,pd plan that the applicable beneficiary is enrolled in2 or 7,,iii7 is provided through an exception or appeal2 and 7,b7 does not include a selected drug 7as referred to under section #aaib7;c77 during a price applicability period 7as defined in section #aaia7;b77#b77 with respect to such drug4 7#c7 ,applicable number of calendar days ,the term applicable number of calendar days means-- 7,a7 with respect to claims for reimbursement submitted electronically1 #ad days2 and 7,b7 with respect to claims for reimbursement submitted otherwise1 #cj days4 7#d7 ,discounted price 7,a7 ,in general ,the term discounted price means1 subject to subparagraphs 7,b7 and 7,c71 with respect to an applicable drug of a manufacturer dispensed during a year to an applicable beneficiary-- 7i7 who has not incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c71 for covered part ,d drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year1 #ij percent of the negotiated price of such drug2 and 7ii7 who has incurred such costs1 as so determined1 in the year that are equal to or exceed such threshold for the year1 #hj percent of the negotiated price of such drug4 7,b7 ,phase-in for certain drugs dispensed to ,,lis beneficiaries 7i7 ,in general ,in the case of an applicable drug of a specified manufacturer 7as defined in clause 7ii77 that is marketed as of the date of enactment of this subparagraph and dispensed for an applicable beneficiary who is a subsidy eligible individual 7as defined in section #ahfj;,d-#ad7;a77#c771 the term discounted price means the specified ,,lis percent 7as defined in clause 7iii77 of the negotiated price of the applicable drug of the manufacturer4 7ii7 ,specified manufacturer 7,i7 ,in general ,in this subparagraph1 subject to subclause 7,,ii71 the term specified manufacturer means a manufacturer of an applicable drug for which1 in #bjba-- 7aa7 the manufacturer had a coverage gap discount agreement under section #ahfj;,d-#ad;,a2 7bb7 the total expenditures for all of the specified drugs of the manufacturer covered by such agreement or agreements for such year and covered under this part during such year represented less than #a4j percent of the total expenditures under this part for all covered ,part ,d drugs during such year2 and 7cc7 the total expenditures for all of the specified drugs of the manufacturer that are single source drugs and biological products covered under part ,b during such year represented less than #a4j percent of the total expenditures under part ,b for all drugs or biological products covered under such part during such year4 7,,ii7 ,specified drugs 7aa7 ,in general ,for purposes of this clause1 the term specified drug means1 with respect to a specified manufacturer1 for #bjba1 an applicable drug that is produced1 prepared1 propagated1 compounded1 converted1 or processed by the manufacturer4 7bb7 ,aggregation rule ,all persons treated as a single employer under subsection 7a7 or 7b7 of section #eb of the ,internal ,revenue ,code of #aihf shall be treated as one manufacturer for purposes of this subparagraph4 ,for purposes of making a determination pursuant to the previous sentence1 an agreement under this section shall require that a manufacturer provide and attest to such information as specified by the ,secretary as necessary4 7,,iii7 ,limitation ,the term specified manufacturer shall not include a manufacturer described in subclause 7,i7 if such manufacturer is acquired after #bjba by another manufacturer that is not a specified manufacturer1 effective at the beginning of the plan year immediately following such acquisition or1 in the case of an acquisition before #bjbd1 effective ,january #a1 #bjbd4 7iii7 ,specified ,,lis percent ,in this subparagraph1 the specified ,,lis percent means1 with respect to a year-- 7,i7 for an applicable drug dispensed for an applicable beneficiary described in clause 7i7 who has not incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c71 for covered part ,d drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year-- 7aa7 for #bjbd1 #ii percent2 7bb7 for #bjbe1 #ih percent2 7cc7 for #bjbf1 #ie percent2 7dd7 for #bjbg1 #ib percent2 and 7ee7 for #bjbh and each subsequent year1 #ij percent2 and 7,,ii7 for an applicable drug dispensed for an applicable beneficiary described in clause 7i7 who has incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c71 for covered part ,d drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year-- 7aa7 for #bjbd1 #ii percent2 7bb7 for #bjbe1 #ih percent2 7cc7 for #bjbf1 #ie percent2 7dd7 for #bjbg1 #ib percent2 7ee7 for #bjbh1 #ij percent2 7ff7 for #bjbi1 #he percent2 and 7gg7 for #bjcj and each subsequent year1 #hj percent4 7,c7 ,phase-in for specified small manufacturers 7i7 ,in general ,in the case of an applicable drug of a specified small manufacturer 7as defined in clause 7ii77 that is marketed as of the date of enactment of this subparagraph and dispensed for an applicable beneficiary1 the term discounted price means the specified small manufacturer percent 7as defined in clause 7iii77 of the negotiated price of the applicable drug of the manufacturer4 7ii7 ,specified small manufacturer 7,i7 ,in general ,in this subparagraph1 subject to subclause 7,,iii71 the term specified small manufacturer means a manufacturer of an applicable drug for which1 in #bjba-- 7aa7 the manufacturer is a specified manufacturer 7as defined in subparagraph 7,b77ii772 and 7bb7 the total expenditures under part ,d for any one of the specified small manufacturer drugs of the manufacturer that are covered by the agreement or agreements under section #ahfj;,d-#ad;,a of such manufacturer for such year and covered under this part during such year are equal to or more than #hj percent of the total expenditures under this part for all specified small manufacturer drugs of the manufacturer that are covered by such agreement or agreements for such year and covered under this part during such year4 7,,ii7 ,specified small manufacturer drugs 7aa7 ,in general ,for purposes of this clause1 the term specified small manufacturer drugs means1 with respect to a specified small manufacturer1 for #bjba1 an applicable drug that is produced1 prepared1 propagated1 compounded1 converted1 or processed by the manufacturer4 7bb7 ,aggregation rule ,all persons treated as a single employer under subsection 7a7 or 7b7 of section #eb of the ,internal ,revenue ,code of #aihf shall be treated as one manufacturer for purposes of this subparagraph4 ,for purposes of making a determination pursuant to the previous sentence1 an agreement under this section shall require that a manufacturer provide and attest to such information as specified by the ,secretary as necessary4 7,,iii7 ,limitation ,the term specified small manufacturer shall not include a manufacturer described in subclause 7,i7 if such manufacturer is acquired after #bjba by another manufacturer that is not a specified small manufacturer1 effective at the beginning of the plan year immediately following such acquisition or1 in the case of an acquisition before #bjbd1 effective ,january #a1 #bjbd4 7iii7 ,specified small manufacturer percent ,in this subparagraph1 the term specified small manufacturer percent means1 with respect to a year-- 7,i7 for an applicable drug dispensed for an applicable beneficiary who has not incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c71 for covered part ,d drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year-- 7aa7 for #bjbd1 #ii percent2 7bb7 for #bjbe1 #ih percent2 7cc7 for #bjbf1 #ie percent2 7dd7 for #bjbg1 #ib percent2 and 7ee7 for #bjbh and each subsequent year1 #ij percent2 and 7,,ii7 for an applicable drug dispensed for an applicable beneficiary who has incurred costs1 as determined in accordance with section #ahfj;,d-#b7;b77#d77;,c71 for covered part ,d drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year-- 7aa7 for #bjbd1 #ii percent2 7bb7 for #bjbe1 #ih percent2 7cc7 for #bjbf1 #ie percent2 7dd7 for #bjbg1 #ib percent2 7ee7 for #bjbh1 #ij percent2 7ff7 for #bjbi1 #he percent2 and 7gg7 for #bjcj and each subsequent year1 #hj percent4 7,d7 ,total expenditures ,for purposes of this paragraph1 the term total expenditures includes1 in the case of expenditures with respect to part ,d1 ingredient costs1 dispensing fees1 sales tax1 and1 if applicable1 vaccine administration fees4 ,the term total expenditures excludes1 in the case of expenditures with respect to part ,b1 expenditures for a drug or biological that are bundled or packaged into the payment for another service4 7,e7 ,special case for certain claims 7i7 ,claims spanning deductible ,in the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall above the annual deductible specified in section #ahfj;,d-#b7;b77#a7 for the year1 the manufacturer of the applicable drug shall provide the discounted price under this section on only the portion of the negotiated price of the applicable drug that falls above such annual deductible4 7ii7 ,claims spanning out-of-pocket threshold ,in the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall entirely below or entirely above the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i7 for the year1 the manufacturer of the applicable drug shall provide the discounted price-- 7,i7 in accordance with subparagraph 7,a77i7 on the portion of the negotiated price of the applicable drug that falls below such threshold2 and 7,,ii7 in accordance with subparagraph 7,a77ii7 on the portion of such price of such drug that falls at or above such threshold4 7#e7 ,manufacturer ,the term manufacturer means any entity which is engaged in the production1 preparation1 propagation1 compounding1 conversion1 or processing of prescription drug products1 either directly or indirectly by extraction from substances of natural origin1 or independently by means of chemical synthesis1 or by a combination of extraction and chemical synthesis4 ,such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under ,state law4 7#f7 ,negotiated price ,the term negotiated price has the meaning given such term in section #dbc4ajj of title #db1 ,code of ,federal ,regulations 7or any successor regulation7 and1 with respect to an applicable drug1 such negotiated price shall include any dispensing fee and1 if applicable1 any vaccine administration fee for the applicable drug4 7#g7 ,qualified retiree prescription drug plan ,the term qualified retiree prescription drug plan has the meaning given such term in section #ahfj;,d-#bb7;a77#b74 #ahfj;,d-#ad;,d4 ,selected drug subsidy program ,with respect to covered part ,d drugs that would be applicable drugs 7as defined in section #ahfj;,d-#ad;,c7g77#b77 but for the application of subparagraph 7,b7 of such section1 the ,secretary shall provide a process whereby1 in the case of an applicable beneficiary 7as defined in section #ahfj;,d-#ad;,c7g77#a77 who1 with respect to a year1 is enrolled in a prescription drug plan or is enrolled in an ,,ma-,,pd plan1 has not incurred costs that are equal to or exceed the annual out-of-pocket threshold specified in section #ahfj;,d-#b7;b77#d77;,b77i71 and is dispensed such a drug the ,secretary 7periodically and on a timely basis7 provides the ,,pdp sponsor or the ,,ma organization offering the plan1 a subsidy with respect to such drug that is equal to #aj percent of the negotiated price 7as defined in section #ahfj;,d-#ad;,c7g77#f77 of such drug4 4 7#b7 ,sunset of ,medicare coverage gap discount program ,section #ahfj;,d-#ad;,a of the ,social ,security ,act 7#db ,u4,s4,c4 #acie-aad;a7 is amended-- 7,a7 in subsection 7a71 in the first sentence1 by striking ,the ,secretary and inserting ,subject to subsection 7h71 the ,secretary2 and 7,b7 by adding at the end the following new subsection3 7h7 ,sunset of program 7#a7 ,in general ,the program shall not apply with respect to applicable drugs dispensed on or after ,january #a1 #bjbd1 and1 subject to paragraph 7#b71 agreements under this section shall be terminated as of such date4 7#b7 ,continued application for applicable drugs dispensed prior to sunset ,the provisions of this section 7including all responsibilities and duties7 shall continue to apply on and after ,january #a1 #bjbd1 with respect to applicable drugs dispensed prior to such date4 4 7#c7 ,inclusion of actuarial value of manufacturer discounts in bids ,section #ahfj;,d-#aa of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7 is amended-- 7,a7 in subsection 7b77#b77;,c77iii7-- 7i7 by striking assumptions regarding the reinsurance and inserting 8assumptions regarding-- 7,i7 the reinsurance 2 and 7ii7 by adding at the end the following3 7,,ii7 for #bjbd and each subsequent year1 the manufacturer discounts provided under section #ahfj;,d-#ad;,c subtracted from the actuarial value to produce such bid2 and 2 and 7,b7 in subsection 7c77#a77;,c7-- 7i7 by striking an actuarial valuation of the reinsurance and inserting 8an actuarial valuation of-- 7i7 the reinsurance 2 7ii7 in clause 7i71 as inserted by clause 7i7 of this subparagraph1 by adding and at the end2 and 7iii7 by adding at the end the following3 7ii7 for #bjbd and each subsequent year1 the manufacturer discounts provided under section #ahfj;,d-#ad;,c2 4 7e7 ,conforming amendments 7#a7 ,section #ahfj;,d-#b of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7 is amended-- 7,a7 in subsection 7a77#b77;,a77i77,i71 by striking 1 or an increase in the initial and inserting or1 for a year preceding #bjbd1 an increase in the initial2 7,b7 in subsection 7c77#a77;,c7-- 7i7 in the subparagraph heading1 by striking at initial coverage limit2 and 7ii7 by inserting for a year preceding #bjbd or the annual out-of-pocket threshold specified in subsection 7b77#d77;,b7 for the year for #bjbd and each subsequent year after subsection 7b77#c7 for the year each place it appears2 and 7,c7 in subsection 7d77#a77;,a71 by striking or an initial and inserting or1 for a year preceding #bjbd1 an initial4 7#b7 ,section #ahfj;,d-#d7;a77#d77;,b77i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7;a77#d77;,b77i77 is amended by striking the initial and inserting for a year preceding #bjbd1 the initial4 7#c7 ,section #ahfj;,d-#ad7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aad7;a77 is amended-- 7,a7 in paragraph 7#a7-- 7i7 in subparagraph 7,c71 by striking ,the continuation and inserting ,for a year preceding #bjbd1 the continuation2 7ii7 in subparagraph 7,d77iii71 by striking #ahfj;,d-#b7;b77#d77;,a77i77,i7 and inserting #ahfj;,d-#b7;b77#d77;,a77i77,i77aa72 and 7iii7 in subparagraph 7,e71 by striking ,the elimination and inserting ,for a year preceding #bjbd1 the elimination2 and 7,b7 in paragraph 7#b7-- 7i7 in subparagraph 7,c71 by striking ,the continuation and inserting ,for a year preceding #bjbd1 the continuation2 and 7ii7 in subparagraph 7,e71 by striking #ahfj;,d-#b7;b77#d77;,a77i77,i7 and inserting #ahfj;,d-#b7;b77#d77;,a77i77,i77aa74 7#d7 ,section #ahfj;,d-#ba7;d77#g7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aca7;d77#g77 is amended by striking section #ahfj;,d-#b7;b77#d77;,b77i7 and inserting section #ahfj;,d-#b7;b77#d77;,c77i74 7#e7 ,section #ahfj;,d-#bb7;a77#b77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#acb7;a77#b77;,a77 is amended-- 7,a7 by striking the value of any discount and inserting the following3 the value of-- 7i7 for years prior to #bjbd1 any discount 2 7,b7 in clause 7i71 as inserted by subparagraph 7,a7 of this paragraph1 by striking the period at the end and inserting 2 and2 and 7,c7 by adding at the end the following new clause3 7ii7 for #bjbd and each subsequent year1 any discount provided pursuant to section #ahfj;,d-#ad;,c4 4 7#f7 ,section #ahfj;,d-#da7;a77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aea7;a77#f77 is amended-- 7,a7 by inserting for a year before #bjbd after #ahfj;,d-#b7;b77#c72 and 7,b7 by inserting for such year before the period4 7#g7 ,section #ahfj;,d-#dc of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aec7 is amended-- 7,a7 in subsection 7a7-- 7i7 by striking paragraph 7#a7 and inserting the following3 7#a7 participate in-- 7,a7 for #bjaa through #bjbc1 the ,medicare coverage gap discount program under section #ahfj;,d-#ad;,a2 and 7,b7 for #bjbd and each subsequent year1 the manufacturer discount program under section #ahfj;,d-#ad;,c2 2 7ii7 by striking paragraph 7#b7 and inserting the following3 7#b7 have entered into and have in effect-- 7,a7 for #bjaa through #bjbc1 an agreement described in subsection 7b7 of section #ahfj;,d-#ad;,a with the ,secretary2 and 7,b7 for #bjbd and each subsequent year1 an agreement described in subsection 7b7 of section #ahfj;,d-#ad;,c with the ,secretary2 and 2 and 7iii7 by striking paragraph 7#c7 and inserting the following3 7#c7 have entered into and have in effect1 under terms and conditions specified by the ,secretary-- 7,a7 for #bjaa through #bjbc1 a contract with a third party that the ,secretary has entered into a contract with under subsection 7d77#c7 of section #ahfj;,d-#ad;,a2 and 7,b7 for #bjbd and each subsequent year1 a contract with a third party that the ,secretary has entered into a contract with under subsection 7d77#c7 of section #ahfj;,d-#ad;,c4 2 and 7,b7 by striking subsection 7b7 and inserting the following3 7b7 ,effective date ,paragraphs 7#a77;,a71 7#b77;,a71 and 7#c77;,a7 of subsection 7a7 shall apply to covered part ,d drugs dispensed under this part on or after ,january #a1 #bjaa1 and before ,january #a1 #bjbd1 and paragraphs 7#a77;,b71 7#b77;,b71 and 7#c77;,b7 of such subsection shall apply to covered part ,d drugs dispensed under this part on or after ,january #a1 #bjbd4 4 7#h7 ,section #aibg of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7 is amended-- 7,a7 in subsection 7c77#a77;,c77i77,,vi71 by inserting before the period at the end the following3 or under the manufacturer discount program under section #ahfj;,d-#ad;,c2 and 7,b7 in subsection 7k77#a77;,b77i77,v71 by inserting before the period at the end the following3 or under section #ahfj;,d-#ad;,c4 7f7 ,implementation for #bjbd and #bjbe ,notwithstanding any other provision of this section1 the ,secretary shall implement this section1 including the amendments made by this section1 for #bjbd and #bjbe by program instruction or otherwise4 7g7 ,funding ,in addition to amounts otherwise available1 there are appropriated to the ,centers for ,medicare ,medicaid ,services1 out of any money in the ,treasury not otherwise appropriated1 #dd1jjj1jjj for fiscal year #bjbb1 #ch1jjj1jjj for fiscal year #bjbc1 and #cb1jjj1jjj for each of fiscal years #bjbd through #bjca1 to remain available until expended1 to carry out the provisions of1 including the amendments made by1 this section4 #cjb4 ,maximum monthly cap on cost-sharing payments under prescription drug plans and ,,ma-,,pd plans 7a7 ,in general ,section #ahfj;,d-#b7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;b771 as amended by section #cja1 is amended-- 7#a7 in paragraph 7#b7-- 7,a7 in subparagraph 7,a71 by striking and 7,d7 and inserting 1 7,d71 and 7,e72 and 7,b7 by adding at the end the following new subparagraph3 7,e7 ,maximum monthly cap on cost-sharing payments 7i7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 each ,,pdp sponsor offering a prescription drug plan and each ,,ma organization offering an ,,ma-,,pd plan shall provide to any enrollee of such plan1 including an enrollee who is a subsidy eligible individual 7as defined in paragraph 7#c7 of section #ahfj;,d-#ad7;a771 the option to elect with respect to a plan year to pay cost-sharing under the plan in monthly amounts that are capped in accordance with this subparagraph4 7ii7 ,determination of maximum monthly cap ,for each month in the plan year for which an enrollee in a prescription drug plan or an ,,ma-,,pd plan has made an election pursuant to clause 7i71 the ,,pdp sponsor or ,,ma organization shall determine a maximum monthly cap 7as defined in clause 7iv77 for such enrollee4 7iii7 ,beneficiary monthly payments ,with respect to an enrollee who has made an election pursuant to clause 7i71 for each month described in clause 7ii71 the ,,pdp sponsor or ,,ma organization shall bill such enrollee an amount 7not to exceed the maximum monthly cap7 for the out-of-pocket costs of such enrollee in such month4 7iv7 ,maximum monthly cap defined ,in this subparagraph1 the term maximum monthly cap means1 with respect to an enrollee-- 7,i7 for the first month for which the enrollee has made an election pursuant to clause 7i71 an amount determined by calculating-- 7aa7 the annual out-of-pocket threshold specified in paragraph 7#d77;,b7 minus the incurred costs of the enrollee as described in paragraph 7#d77;,c72 divided by 7bb7 the number of months remaining in the plan year2 and 7,,ii7 for a subsequent month1 an amount determined by calculating-- 7aa7 the sum of any remaining out-of-pocket costs owed by the enrollee from a previous month that have not yet been billed to the enrollee and any additional out-of-pocket costs incurred by the enrollee2 divided by 7bb7 the number of months remaining in the plan year4 7v7 ,additional requirements ,the following requirements shall apply with respect to the option to make an election pursuant to clause 7i7 under this subparagraph3 7,i7 ,secretarial responsibilities ,the ,secretary shall provide information to part ,d eligible individuals on the option to make such election through educational materials1 including through the notices provided under section #ahjd7;a74 7,,ii7 ,timing of election ,an enrollee in a prescription drug plan or an ,,ma-,,pd plan may make such an election-- 7aa7 prior to the beginning of the plan year2 or 7bb7 in any month during the plan year4 7,,iii7 ,,pdp sponsor and ma organization responsibilities ,each ,,pdp sponsor offering a prescription drug plan or ,,ma organization offering an ,,ma-,,pd plan-- 7aa7 may not limit the option for an enrollee to make such an election to certain covered part ,d drugs2 7bb7 shall1 prior to the plan year1 notify prospective enrollees of the option to make such an election in promotional materials2 7cc7 shall include information on such option in enrollee educational materials2 7dd7 shall have in place a mechanism to notify a pharmacy during the plan year when an enrollee incurs out-of-pocket costs with respect to covered part ,d drugs that make it likely the enrollee may benefit from making such an election2 7ee7 shall provide that a pharmacy1 after receiving a notification described in item 7dd7 with respect to an enrollee1 informs the enrollee of such notification2 7ff7 shall ensure that such an election by an enrollee has no effect on the amount paid to pharmacies 7or the timing of such payments7 with respect to covered part ,d drugs dispensed to the enrollee2 and 7gg7 shall have in place a financial reconciliation process to correct inaccuracies in payments made by an enrollee under this subparagraph with respect to covered part ,d drugs during the plan year4 7,,iv7 ,failure to pay amount billed ,if an enrollee fails to pay the amount billed for a month as required under this subparagraph1 the election of the enrollee pursuant to clause 7i7 shall be terminated and the enrollee shall pay the cost-sharing otherwise applicable for any covered part ,d drugs subsequently dispensed to the enrollee up to the annual out-of-pocket threshold specified in paragraph 7#d77;,b74 7,v7 ,clarification regarding past due amounts ,nothing in this subparagraph shall be construed as prohibiting a ,,pdp sponsor or an ,,ma organization from billing an enrollee for an amount owed under this subparagraph4 7,,vi7 ,treatment of unsettled balances ,any unsettled balances with respect to amounts owed under this subparagraph shall be treated as plan losses and the ,secretary shall not be liable for any such balances outside of those assumed as losses estimated in plan bids4 2 and 7#b7 in paragraph 7#d7-- 7,a7 in subparagraph 7,c71 by striking in subparagraph 7,e7 and inserting in subparagraph 7,e7 and subject to subparagraph 7,f72 and 7,b7 by adding at the end the following new subparagraph3 7,f7 ,inclusion of costs paid under maximum monthly cap option ,in applying subparagraph 7,a71 with respect to an enrollee who has made an election pursuant to clause 7i7 of paragraph 7#b77;,e71 costs shall be treated as incurred if such costs are paid by a ,,pdp sponsor or an ,,ma organization under the option provided under such paragraph4 4 7b7 ,application to alternative prescription drug coverage ,section #ahfj;,d-#b7;c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;c77 is amended by adding at the end the following new paragraph3 7#d7 ,same maximum monthly cap on cost-sharing ,for plan years beginning on or after ,january #a1 #bjbe1 the maximum monthly cap on cost-sharing payments under the option provided under subsection 7b77#b77;,e7 shall apply to such coverage4 4 7c7 ,implementation for #bjbe ,the ,secretary shall implement this section1 including the amendments made by this section1 for #bjbe by program instruction or otherwise4 7d7 ,funding ,in addition to amounts otherwise available1 there are appropriated to the ,centers for ,medicare ,medicaid ,services1 out of any money in the ,treasury not otherwise appropriated1 #a1jjj1jjj for each of fiscal years #bjbb through #bjca1 to remain available until expended1 to carry out the provisions of1 including the amendments made by1 this section4 ,,iv ,repeal of ,certain ,prescription ,drug ,rebate ,rule #dja4 ,prohibiting implementation of rule relating to eliminating the anti-kickback statute safe harbor protection for prescription drug rebates ,beginning ,january #a1 #bjbf1 the ,secretary of ,health and ,human ,services shall not implement1 administer1 or enforce the provisions of the final rule published by the ,office of the ,inspector ,general of the ,department of ,health and ,human ,services on ,november #cj1 #bjbj1 and titled ,fraud and ,abuse2 ,removal of ,safe ,harbor ,protection for ,rebates ,involving ,prescription ,pharmaceuticals and ,creation of ,new ,safe ,harbor ,protection for ,certain ,point-of-,sale ,reductions in ,price on ,prescription ,pharmaceuticals and ,certain ,pharmacy ,benefit ,manager ,service ,fees 7#he ,fed4 ,reg4 #gffff74 ,v ,miscellaneous #eja4 ,appropriate cost-sharing for certain insulin products under ,medicare part ,d 7a7 ,in general ,section #ahfj;,d-#b of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7 is amended-- 7#a7 in subsection 7b7-- 7,a7 in paragraph 7#a77;,a71 by striking ,the coverage and inserting ,subject to paragraph 7#h71 the coverage2 7,b7 in paragraph 7#b77;,a71 by striking and 7,d7 and inserting and 7,d7 and paragraph 7#h72 7,c7 in paragraph 7#c77;,a71 by striking and 7#d7 and inserting 7#d71 and 7#h72 7,d7 in paragraph 7#d77;,a77i71 by striking ,the coverage and inserting ,subject to paragraph 7#h71 the coverage2 and 7,e7 by adding at the end the following new paragraph3 7#h7 ,treatment of cost-sharing for certain insulin products 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbc1 the following shall apply with respect to insulin products 7as defined in subparagraph 7,b773 7i7 ,no application of deductible ,the deductible under paragraph 7#a7 shall not apply with respect to such insulin products4 7ii7 ,application of cost-sharing 7,i7 ,plan year #bjbc ,for plan year #bjbc1 the coverage provides benefits for such insulin products1 regardless of whether an individual has reached the initial coverage limit under paragraph 7#c7 or the out-of-pocket threshold under paragraph 7#d71 with cost-sharing that is equal to the applicable copayment amount4 7,,ii7 ,plan year #bjbd and subsequent plan years ,for plan year #bjbd and subsequent plan years1 the coverage provides benefits for such insulin products1 prior to an individual reaching the out-of-pocket threshold under paragraph 7#d71 with cost-sharing that is equal to the applicable copayment amount4 7,,iii7 ,applicable copayment amount ,for purposes of this clause1 the term applicable copayment amount means1 with respect to an insulin product under a prescription drug plan or an ,,ma-,,pd plan1 an amount that is not more than #ce4 7,b7 ,insulin product ,for purposes of this paragraph1 the term insulin product means an insulin product that is approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act or licensed under section #cea of the ,public ,health ,service ,act and marketed pursuant to such approval or licensure1 including any insulin product that has been deemed to be licensed under section #cea of the ,public ,health ,service ,act pursuant to section #gjjb7;e77#d7 of the ,biologics ,price ,competition and ,innovation ,act of #bjji and marketed pursuant to such section4 2 and 7#b7 in subsection 7c71 by adding at the end the following new paragraph3 7#d7 ,treatment of cost-sharing for insulin products ,the coverage is provided in accordance with subsection 7b77#h74 4 7b7 ,conforming amendments to cost-,sharing for low-,income individuals ,section #ahfj;,d-#ad7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aad7;a77 is amended-- 7#a7 in paragraph 7#a7-- 7,a7 in subparagraph 7,d77iii71 by adding at the end the following new sentence3 ,for plan year #bjbc and subsequent plan years1 the copayment amount applicable under the preceding sentence to an insulin product 7as defined in section #ahfj;,d-#b7;b77#h77;,b77 furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or ,,ma-,,pd plan in which the individual is enrolled42 and 7,b7 in subparagraph 7,e71 by inserting the following before the period at the end or under section #ahfj;,d-#b7;b77#h7 in the case of an insulin product 7as defined in subparagraph 7,b7 of such section72 and 7#b7 in paragraph 7#b7-- 7,a7 in subparagraph 7,d71 by adding at the end the following new sentence3 ,for plan year #bjbc and subsequent plan years1 the amount of the coinsurance applicable under the preceding sentence to an insulin product 7as defined in section #ahfj;,d-#b7;b77#h77;,b77 furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or ,,ma-,,pd plan in which the individual is enrolled42 and 7,b7 in subparagraph 7,e71 by adding at the end the following new sentence3 ,for plan year #bjbc1 the amount of the copayment or coinsurance applicable under the preceding sentence to an insulin product 7as defined in section #ahfj;,d-#b7;b77#h77;,b77 furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or ,,ma-,,pd plan in which the individual is enrolled44 7c7 ,implementation ,the ,secretary shall implement this section for plan years #bjbc and #bjbd by program instruction or otherwise4 #ejb4 ,coverage of adult vaccines recommended by the ,advisory ,committee on ,immunization ,practices under ,medicare part ,d 7a7 ,ensuring treatment of cost-,sharing is consistent with treatment of vaccines under medicare part b ,section #ahfj;,d-#b of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb71 as amended by section #eja1 is further amended-- 7#a7 in subsection 7b7-- 7,a7 in paragraph 7#a77;,a71 by striking paragraph 7#h7 and inserting paragraphs 7#h7 and 7#i72 7,b7 in paragraph 7#b77;,a71 by striking paragraph 7#h7 and inserting paragraphs 7#h7 and 7#i72 7,c7 in paragraph 7#c77;,a71 by striking and 7#h7 and inserting 7#h71 and 7#i72 7,d7 in paragraph 7#d77;,a77i71 by striking paragraph 7#h7 and inserting paragraphs 7#h7 and 7#i72 and 7,e7 by adding at the end the following new paragraph3 7#i7 ,treatment of cost-sharing for adult vaccines recommended by the advisory committee on immunization practices consistent with treatment of vaccines under part b 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbd1 the following shall apply with respect to an adult vaccine recommended by the ,advisory ,committee on ,immunization ,practices 7as defined in subparagraph 7,b773 7i7 ,no application of deductible ,the deductible under paragraph 7#a7 shall not apply with respect to such vaccine4 7ii7 ,no application of coinsurance or any other cost-sharing ,there shall be no coinsurance or other cost-sharing under this part with respect to such vaccine1 regardless of whether for costs below1 at1 or above the initial coverage limit under paragraph 7#c7 or the out-of-pocket threshold under paragraph 7#d74 7,b7 ,adult vaccines recommended by the advisory committee on immunization practices ,for purposes of this paragraph1 the term adult vaccine recommended by the ,advisory ,committee on ,immunization ,practices means a covered part ,d drug that is a vaccine licensed under section #cea of the ,public ,health ,service ,act for use by adult populations and administered in accordance with recommendations of the ,advisory ,committee on ,immunization ,practices of the ,centers for ,disease ,control and ,prevention4 2 and 7#b7 in subsection 7c71 by adding at the end the following new paragraph3 7#e7 ,treatment of cost-sharing for adult vaccines recommended by the advisory committee on immunization practices ,the coverage is in accordance with subsection 7b77#i74 4 7b7 ,conforming amendments to cost-,sharing for low-,income individuals ,section #ahfj;,d-#ad7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aad7;a771 as amended by section #eja1 is further amended-- 7#a7 in paragraph 7#a77;,d71 in each of clauses 7ii7 and 7iii71 by striking ,in the case and inserting ,subject to paragraph 7#f71 in the case2 7#b7 in paragraph 7#b7-- 7,a7 in subparagraph 7,b71 by striking ,a reduction and inserting ,subject to paragraph 7#f71 a reduction2 7,b7 in subparagraph 7,d71 by striking ,the substitution and inserting ,subject to paragraph 7#f71 the substitution2 and 7,c7 in subparagraph 7,e71 by striking subsection 7c7 and inserting paragraph 7#f7 and subsection 7c72 and 7#c7 by adding at the end the following new paragraph3 7#f7 ,no application of cost-sharing for adult vaccines recommended by the advisory committee on immunization practices ,for plan years beginning on or after ,january #a1 #bjbd1 there shall be no cost-sharing under this section1 including no annual deductible applicable under this section1 with respect to an adult vaccine recommended by the ,advisory ,committee on ,immunization ,practices 7as defined in subparagraph 7,b7 of such section74 4 7c7 ,rule of construction ,nothing in this section shall be construed as limiting coverage under part ,d of title ,,xviii of the ,social ,security ,act for vaccines that are not recommended by the ,advisory ,committee on ,immunization ,practices4 7d7 ,implementation for #bjbd ,the ,secretary shall implement this section1 including the amendments made by this section1 for #bjbd by program instruction or otherwise4 #ejc4 ,payment for biosimilar biological products during initial period ,section #ahdg;,a7c77#d7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#d77 is amended-- 7#a7 in each of subparagraphs 7,a7 and 7,b71 by redesignating clauses 7i7 and 7ii7 as subclauses 7,i7 and 7,,ii71 respectively1 and moving such subclauses #b ems to the right2 7#b7 by redesignating subparagraphs 7,a7 and 7,b7 as clauses 7i7 and 7ii7 and moving such clauses #b ems to the right2 7#c7 by striking unavailable4--,in the case and inserting 8unavailable4-- 7,a7 ,in general ,subject to subparagraph 7,b71 in the case 2 and 7#d7 by adding at the end the following new subparagraph3 7,b7 ,limitation on payment amount for biosimilar biological products during initial period ,in the case of a biosimilar biological product furnished on or after ,july #a1 #bjbc1 during the initial period described in subparagraph 7,a7 with respect to the biosimilar biological product1 the amount payable under this section for the biosimilar biological product is the lesser of the following3 7i7 ,the amount determined under clause 7ii7 of such subparagraph for the biosimilar biological product4 7ii7 ,the amount determined under subsection 7b77#a77;,b7 for the reference biological product4 4 #ejd4 ,temporary increase in ,medicare part ,b payment for certain biosimilar biological products ,section #ahdg;,a7b77#h7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7b77#h77 is amended-- 7#a7 by redesignating subparagraphs 7,a7 and 7,b7 as clauses 7i7 and 7ii71 respectively1 and moving the margin of each such redesignated clause #b ems to the right2 7#b7 by striking product4--,the amount and inserting the following3 8product4-- 7,a7 ,in general ,subject to subparagraph 7,b71 the amount 2 and 7#c7 by adding at the end the following new subparagraph3 7,b7 ,temporary payment increase 7i7 ,in general ,in the case of a qualifying biosimilar biological product that is furnished during the applicable #e-year period for such product1 the amount specified in this paragraph for such product with respect to such period is the sum determined under subparagraph 7,a71 except that clause 7ii7 of such subparagraph shall be applied by substituting #h percent for #f percent4 7ii7 ,applicable #e-year period ,for purposes of clause 7i71 the applicable #e-year period for a qualifying biosimilar biological product is-- 7,i7 in the case of such a product for which payment was made under this paragraph as of ,march #ca1 #bjbb1 the #e-year period beginning on ,april #a1 #bjbb2 and 7,,ii7 in the case of such a product for which payment is first made under this paragraph during a calendar quarter during the period beginning ,april #a1 #bjbb1 and ending ,march #ca1 #bjbg1 the #e-year period beginning on the first day of such calendar quarter during which such payment is first made4 7iii7 ,qualifying biosimilar biological product defined ,for purposes of this subparagraph1 the term qualifying biosimilar biological product means a biosimilar biological product described in paragraph 7#a77;,c7 with respect to which-- 7,i7 in the case of a product described in clause 7ii77,i71 the average sales price under paragraph 7#h77;,a77i7 for a calendar quarter during the #e-year period described in such clause is not more than the average sales price under paragraph 7#d77;,a7 for such quarter for the reference biological product2 and 7,,ii7 in the case of a product described in clause 7ii77,,ii71 the average sales price under paragraph 7#h77;,a77i7 for a calendar quarter during the #e-year period described in such clause is not more than the average sales price under paragraph 7#d77;,a7 for such quarter for the reference biological product4 4 #eje4 ,improving access to adult vaccines under ,medicaid and ,,chip 7a7 ,medicaid 7#a7 ,requiring coverage of adult vaccinations 7,a7 ,in general ,section #aijb7;a77#aj77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;a7a77#aj77;,a77 is amended in the matter preceding clause 7i7 by inserting 7#ac77;,b71 after 7#e714 7,b7 ,medically needy ,section #aijb7;a77#aj77;,c77iv7 of such ,act 7#db ,u4,s4,c4 #acif;a7a77#aj77;,c77iv77 is amended by inserting 1 7#ac77;,b71 after 7#e74 7#b7 ,no cost-sharing for vaccinations 7,a7 ,general cost-sharing limitations ,section #aiaf of the ,social ,security ,act 7#db ,u4,s4,c4 #acifo7 is amended-- 7i7 in subsection 7a77#b7-- 7,i7 in subparagraph 7,g71 by inserting a comma after ,state plan2 7,,ii7 in subparagraph 7,h71 by striking 2 or and inserting a comma2 7,,iii7 in subparagraph 7,i71 by striking 2 and and inserting 1 or2 and 7,,iv7 by adding at the end the following new subparagraph3 7,j7 vaccines described in section #aije7;a77#ac77;,b7 and the administration of such vaccines2 and 2 and 7ii7 in subsection 7b77#b7-- 7,i7 in subparagraph 7,g71 by inserting a comma after ,state plan2 7,,ii7 in subparagraph 7,h71 by striking 2 or and inserting a comma2 7,,iii7 in subparagraph 7,i71 by striking 2 and and inserting 1 or2 and 7,,iv7 by adding at the end the following new subparagraph3 7,j7 vaccines described in section #aije7;a77#ac77;,b7 and the administration of such vaccines2 and 4 7,b7 ,application to alternative cost-sharing ,section #aiaf;,a7b77#c77;,b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifo-#a7;b77#c77;,b77 is amended by adding at the end the following new clause3 7xiv7 ,vaccines described in section #aije7;a77#ac77;,b7 and the administration of such vaccines4 4 7#c7 ,increased ,,fmap for adult vaccines ,section #aije7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7b77 is amended-- 7,a7 by striking and 7#e7 and inserting 7#e72 7,b7 by striking services and vaccines described in subparagraphs 7,a7 and 7,b7 of subsection 7a77#ac71 and prohibits cost-sharing for such services and vaccines and inserting services described in subsection 7a77#ac77;,a71 and prohibits cost-sharing for such services2 7,c7 by striking medical assistance for such services and vaccines and inserting medical assistance for such services2 and 7,d7 by inserting 1 and 7#f7 during the first #h fiscal quarters beginning on or after the effective date of this clause1 in the case of a ,state which1 as of the date of enactment of the ,act titled ,an ,act to provide for reconciliation pursuant to title ,,ii of ,s4 ,con4 ,res4 #ad1 provides medical assistance for vaccines described in subsection 7a77#ac77;,b7 and their administration and prohibits cost-sharing for such vaccines1 the ,federal medical assistance percentage1 as determined under this subsection and subsection 7y71 shall be increased by #a percentage point with respect to medical assistance for such vaccines before the first period4 7b7 ,,chip 7#a7 ,requiring coverage of adult vaccinations ,section #bajc7;c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acig;cc7c77 is amended by adding at the end the following paragraph3 7#ab7 ,required coverage of approved1 recommended adult vaccines and their administration ,regardless of the type of coverage elected by a ,state under subsection 7a71 if the ,state child health plan or a waiver of such plan provides child health assistance or pregnancy-related assistance 7as defined in section #baab7 to an individual who is #ai years of age or older1 such assistance shall include coverage of vaccines described in section #aije7;a77#ac77;,b7 and their administration4 4 7#b7 ,no cost-sharing for vaccinations ,section #bajc7;e77#b7 of such ,act 7#db ,u4,s4,c4 #acig;cc7e77#b77 is amended by inserting vaccines described in subsection 7c77#ab7 7and the administration of such vaccines71 after in vitro diagnostic products described in subsection 7c77#aj7 7and administration of such products714 7c7 ,effective date ,the amendments made by this section take effect on the #ast day of the #ast fiscal quarter that begins on or after the date that is #a year after the date of enactment of this ,act and shall apply to expenditures made under a ,state plan or waiver of such plan under title ,,xix of the ,social ,security ,act 7#db ,u4,s4,c4 #acif through #acifw-#f7 or under a ,state child health plan or waiver of such plan under title ,,xxi of such ,act 7#db ,u4,s4,c4 #acig;aa through #acigmm7 on or after such effective date4 ,,vi ,additional ,insulin ,policies #fja4 ,,erisa requirements with respect to cost-sharing for certain insulin products 7a7 ,in general ,subpart ,b of part #g of subtitle ,b of title ,i of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #aahe et seq47 is amended by adding at the end the following3 #gbf4 ,requirements with respect to cost-sharing for certain insulin products 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbc1 a group health plan or health insurance issuer offering group health insurance coverage shall provide coverage of selected insulin products1 and with respect to such products1 shall not-- 7#a7 apply any deductible2 or 7#b7 impose any cost-sharing in excess of the lesser of1 per #cj-;day supply-- 7,a7 #ce2 or 7,b7 the amount equal to #be percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage1 including price concessions received by or on behalf of third-party entities providing services to the plan or coverage1 such as pharmacy benefit management services4 7b7 ,definitions ,in this section3 7#a7 ,selected insulin products ,the term selected insulin products means at least one of each dosage form 7such as vial1 pump1 or inhaler dosage forms7 of each different type 7such as rapid-acting1 short-acting1 intermediate-acting1 long-acting1 ultra long-acting1 and premixed7 of insulin 7as defined below71 when available1 as selected by the group health plan or health insurance issuer4 7#b7 ,insulin defined ,the term insulin means insulin that is licensed under subsection 7a7 or 7k7 of section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 and continues to be marketed under such section1 including any insulin product that has been deemed to be licensed under section #cea7;a7 of such ,act pursuant to section #gjjb7;e77#d7 of the ,biologics ,price ,competition and ,innovation ,act of #bjji 7,public ,law #aaa-adh7 and continues to be marketed pursuant to such licensure4 7c7 ,out-of-,network providers ,nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider1 or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection 7a7 for selected insulin products described in this section that are delivered by an out-of-network provider4 7d7 ,rule of construction ,subsection 7a7 shall not be construed to require coverage of1 or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection 7a7 on1 insulin products that are not selected insulin products1 to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under ,federal and applicable ,state law4 7e7 ,application of cost-,sharing towards deductibles and out-of-,pocket maximums ,any cost-sharing payments made pursuant to subsection 7a77#b7 shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage4 4 7b7 ,clerical amendment ,the table of contents in section #a of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #ajja et seq47 is amended by inserting after the item relating to section #gbe the following3 ,sec4 #gbf4 ,requirements with respect to cost-sharing for certain insulin products4 4 #fjb4 ,public ,health ,service ,act requirements with respect to cost-sharing for insulin products 7a7 ,in general ,part ,d of title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#aaa et seq47 is amended by adding at the end the following3 #bgii;,a-#aa4 ,requirements with respect to cost-sharing for certain insulin products 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbc1 a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products1 and with respect to such products1 shall not-- 7#a7 apply any deductible2 or 7#b7 impose any cost-sharing in excess of the lesser of1 per #cj-;day supply-- 7,a7 #ce2 or 7,b7 the amount equal to #be percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage1 including price concessions received by or on behalf of third-party entities providing services to the plan or coverage1 such as pharmacy benefit management services4 7b7 ,definitions ,in this section3 7#a7 ,selected insulin products ,the term selected insulin products means at least one of each dosage form 7such as vial1 pump1 or inhaler dosage forms7 of each different type 7such as rapid-acting1 short-acting1 intermediate-acting1 long-acting1 ultra long-acting1 and premixed7 of insulin 7as defined below71 when available1 as selected by the group health plan or health insurance issuer4 7#b7 ,insulin defined ,the term insulin means insulin that is licensed under subsection 7a7 or 7k7 of section #cea and continues to be marketed under such section1 including any insulin product that has been deemed to be licensed under section #cea7;a7 pursuant to section #gjjb7;e77#d7 of the ,biologics ,price ,competition and ,innovation ,act of #bjji and continues to be marketed pursuant to such licensure4 7c7 ,out-of-,network providers ,nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider1 or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection 7a7 for selected insulin products described in this section that are delivered by an out-of-network provider4 7d7 ,rule of construction ,subsection 7a7 shall not be construed to require coverage of1 or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection 7a7 on1 insulin products that are not selected insulin products1 to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under ,federal and applicable ,state law4 7e7 ,application of cost-,sharing towards deductibles and out-of-,pocket maximums ,any cost-sharing payments made pursuant to subsection 7a77#b7 shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage4 4 7b7 ,no effect on other cost-,sharing ,section #acjb7;d77#b7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjbb7;d77#b77 is amended by adding at the end the following new subparagraph3 7,d7 ,special rule relating to insulin coverage ,the exemption of coverage of selected insulin products 7as defined in section #bgii;,a-#aa7;b7 of the ,public ,health ,service ,act7 from the application of any deductible pursuant to section #bgii;,a-#aa7;a77#a7 of such ,act1 section #gbf7;a77#a7 of the ,employee ,retirement ,income ,security ,act of #aigd1 or section #ihbf7;a77#a7 of the ,internal ,revenue ,code of #aihf shall not be considered when determining the actuarial value of a qualified health plan under this subsection4 4 7c7 ,coverage of certain insulin products under catastrophic plans ,section #acjb7;e7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjbb7;e77 is amended by adding at the end the following3 7#d7 ,coverage of certain insulin products 7,a7 ,in general ,notwithstanding paragraph 7#a77;,b77i71 a health plan described in paragraph 7#a7 shall provide coverage of selected insulin products1 in accordance with section #bgii;,a-#aa of the ,public ,health ,service ,act1 for a plan year before an enrolled individual has incurred cost-sharing expenses in an amount equal to the annual limitation in effect under subsection 7c77#a7 for the plan year4 7,b7 ,terminology ,for purposes of subparagraph 7,a7-- 7i7 the term selected insulin products has the meaning given such term in section #bgii;,a-#aa7;b7 of the ,public ,health ,service ,act2 and 7ii7 the requirements of section #bgii;,a-#aa of such ,act shall be applied by deeming each reference in such section to individual health insurance coverage to be a reference to a plan described in paragraph 7#a74 4 #fjc4 ,,irc requirements with respect to cost-sharing for certain insulin products 7a7 ,in general ,subchapter ,b of chapter #ajj is amended by adding at the end the following new section3 #ihbf4 ,requirements with respect to cost-sharing for certain insulin products 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbc1 a group health plan shall provide coverage of selected insulin products1 and with respect to such products1 shall not-- 7#a7 apply any deductible2 or 7#b7 impose any cost-sharing in excess of the lesser of1 per #cj-;day supply-- 7,a7 #ce2 or 7,b7 the amount equal to #be percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan1 including price concessions received by or on behalf of third-party entities providing services to the plan1 such as pharmacy benefit management services4 7b7 ,definitions ,in this section3 7#a7 ,selected insulin products ,the term selected insulin products means at least one of each dosage form 7such as vial1 pump1 or inhaler dosage forms7 of each different type 7such as rapid-acting1 short-acting1 intermediate-acting1 long-acting1 ultra long-acting1 and premixed7 of insulin 7as defined below71 when available1 as selected by the group health plan4 7#b7 ,insulin defined ,the term insulin means insulin that is licensed under subsection 7a7 or 7k7 of section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 and continues to be marketed under such section1 including any insulin product that has been deemed to be licensed under section #cea7;a7 of such ,act pursuant to section #gjjb7;e77#d7 of the ,biologics ,price ,competition and ,innovation ,act of #bjji 7,public ,law #aaa-adh7 and continues to be marketed pursuant to such licensure4 7c7 ,out-of-,network providers ,nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider1 or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection 7a7 for selected insulin products described in this section that are delivered by an out-of-network provider4 7d7 ,rule of construction ,subsection 7a7 shall not be construed to require coverage of1 or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection 7a7 on1 insulin products that are not selected insulin products1 to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under ,federal and applicable ,state law4 7e7 ,application of cost-,sharing towards deductibles and out-of-,pocket maximums ,any cost-sharing payments made pursuant to subsection 7a77#b7 shall be counted toward any deductible or out-of-pocket maximum that applies under the plan4 4 7b7 ,clerical amendment ,the table of sections for subchapter ,b of chapter #ajj is amended by adding at the end the following new item3 ,sec4 #ihbf4 ,requirements with respect to cost-sharing for certain insulin products4 4